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“There is always a way to do it better… find it!” 
Thomas A Edison (Feb 11, 1847–Oct 18, 1931) 
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Dedication 
Meinen geliebten Eltern sowie meiner Schwester für die stetige Unterstützung und Liebe.  
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Preface 
Is it appropriate to treat newly diagnosed cancer patients with all existing therapies to achieve a 
survival benefit? Side effects, toxicities and also high costs restrain such an approach. To enhance the 
efficiency of cancer therapies, it is of highest importance to apply accurate, validated and powerful 
markers predictive of treatment response. The aim of this work was to assess the cost-effectiveness of 
predictive markers in breast and colorectal cancer settings. The fundamentals of pharmacoeconomic 
evaluations, the burden of breast and colorectal cancer and the role of predictive markers in oncology 
are first introduced. The core data is then presented in form of the following three publications or 
submitted manuscripts for publication:  
1. Human epidermal growth factor receptor 2 expression in early breast cancer patients: a 
Swiss cost–effectiveness analysis of different predictive assay strategies 
Blank PR, Schwenkglenks M, Moch H, Szucs TD 
Breast Cancer Res Treat. 2010 Apr 3.  
Impact factor: 4.696 
 
2. Cost Effectiveness of Cytotoxic and Targeted Therapy for Metastatic Breast Cancer: A 
Critical and Systematic Review
 
Blank PR, Dedes KJ, Szucs TD 
Pharmacoeconomics. 2010 Aug 1;28(8):629-47 
Impact factor: 2.612 
 
3. Predictive testing for KRAS and BRAF mutations in the treatment of metastatic 
colorectal cancer – A cost-effectiveness analysis from the Swiss perspective 
 
Blank PR, Moch H, Szucs TD, Schwenkglenks M 
Submitted manuscript 
 
The work of this thesis was performed in the working group of Health Economics at the Institute of 
Social and Preventive Medicine at the University of Zurich in collaboration with the Institute of Surgical 
Pathology at the Department of Pathology at the University Hospital Zurich. The work was funded by 
an unrestricted educational grant of the ETH Foundation and the Competence Center for Systems 
Physiology and Metabolic Diseases (CC-SPMD), Zurich, Switzerland.  
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Part I - Summary 
Background. Despite extensive progress in surgery and chemotherapy treatments, patients with 
advanced cancer in particular generally have a poor prognosis. Monoclonal antibody therapies against 
molecular markers like the epidermal growth factor receptor (EGFR) or the human epidermal growth 
factor receptor 2 (HER-2) have achieved substantial benefits in colorectal and breast cancer patients, 
but also increased health care costs. However, only those breast cancer patients with HER-2 protein 
overexpression or HER-2 oncogene amplification profit from trastuzumab, a monoclonal antibody 
targeted at HER-2. Recent clinical evidence has linked KRAS and BRAF mutations with resistance to 
EGFR antibodies like cetuximab. HER-2 status can be determined by immunohistochemistry (IHC) 
and/or fluorescence in situ hybridisation (FISH), whereas KRAS and BRAF mutations are generally 
identified by DNA sequencing analyses. It is a clinical and economic need to identify those patients 
who benefit from the expensive anti-cancer drugs. Data on the health economic consequence of 
predictive tests for HER-2, KRAS or BRAF are limited or even lacking.  
Here, we assessed the cost-effectiveness of different test strategies for HER-2 in adjuvant breast 
cancer treatment. In addition, we determined the health economic impact of testing for KRAS and 
BRAF mutations in advanced, chemorefractory colorectal cancer patients from the perspective of the 
Swiss health system. Finally, pharmacoeconomic studies with regard to metastatic breast cancer were 
systematically and critically reviewed.  
Methods. A life-long Markov state transition model was constructed to determine costs (!) and 
effectiveness (quality-adjusted life-years, QALYs) of predictive testing in hypothetical cohorts of early 
breast cancer and advanced chemorefractory colorectal cancer patients. Predictive testing strategies 
for the first model included HER-2 assay strategies based on IHC, FISH, both combined, or FISH 
confirmation of IHC-2+ for the breast cancer setting. The second model in the colorectal setting 
determined the health economic impact of the following strategies: KRAS testing, KRAS testing with 
subsequent BRAF testing of tumours with KRAS wild-type (KRAS/BRAF), cetuximab treatment without 
testing. Costs and effects of no trastuzumab or no cetuximab treatment of all breast or colorectal 
cancer patients, respectively, were used as reference values. For the review article, cost-effectiveness 
and cost-utility analysis of various treatment regimens for metastatic breast cancer were identified by 
literature and reference searches. The focus of the review was to critically assess the incremental 
cost-effectiveness ratios reported, the quality of the pharmacoeconomic evaluations and key modelling 
parameters included. Guidelines for critical appraisal of health economic studies built the basis of the 
appraisal.  
Results. In the first project, FISH testing was the most cost–effective strategy with an incremental 
cost–effectiveness ratio (ICER) of ! 12’245 per QALY gained compared to no trastuzumab treatment. 
The second model for the colorectal setting, determined KRAS/BRAF testing as the most cost-
effective approach when compared to the reference strategy (ICER: ! 67’779/QALY). All base-case 
results remained the preferred option in deterministic and probabilistic sensitivity analyses.!!
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Pharamcoeconomic studies regarding metastatic breast cancer therapies presented diverse results. 
Clinical evidence does not propose one conventional chemotherapy treatment as favourable. 
However, cost-effectiveness ratios of cytotoxic drugs are generally favourable. Trastuzumab is 
currently the only antibody-based targeted drug established for metastatic breast cancer with diverse 
pharmacoeconomic outcomes. 
Conclusion. Markers with a high predictive value such as HER-2 protein overexpression/ gene 
amplification or KRAS and BRAF gene-mutations can help identifying patients who are likely or 
unlikely to benefit from monoclonal antibody-based cancer therapies such as trastuzumab or 
cetuximab. In the early breast cancer setting, primary FISH testing with subsequent trastuzumab 
treatment of HER-2-positive cancers is a cost-effective and preferable approach. Despite substantial 
costs of predictive testing, it is economically favourable to identify metastatic colorectal patients with 
KRAS and BRAF wild-type status. Using state-of-the-art health economic methodology, we aimed at 
dealing, at least in part, with the current lack of economic data on this topic. Our results should be of 
relevance for oncologists, pathologists, and health policy makers.  
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Part I - Zusammenfassung 
Hintergrund. Trotz eines enormen Fortschrittes in der Chirurgie und neuen Chemotherapeutika 
haben insbesondere Patienten mit fortgeschrittenem Krebsstadium im Allgemeinen eine schlechte 
Prognose. Monoklonale Antikörpertherapien, welche gegen molekulare Angriffspunkte, wie den 
epidermalen Wachstumsfaktor - Rezeptor (EGFR) oder den humanen epidermalen Wachstumsfaktor - 
Rezeptor 2 (HER-2) gerichtet sind, haben sowohl beim kolorektalen Karzinom wie auch beim Mamma 
- Karzinom einen wesentlichen Überlebensvorteil erzielt, jedoch auch das Gesundheitswesen mit 
erheblichen Mehrkosten belastet. Neue Studien haben gezeigt, dass nur jene Brustkrebspatientinnen 
mit einer HER-2 Protein Überexpression oder einer HER-2 Onkogen - Amplifikation von der 
monoklonalen Antikörpertherapie mit Trastuzumab (Herceptin®, Roche, Switzerland) profitieren 
können. Beim kolorektalen Karzinom werden bestimmte Mutationen in der Gensequenz der Proto-
onkogene KRAS oder BRAF mit einer Resistenz gegen EGFR- Antikörper wie Cetuximab (Erbitux®, 
Merck AG) assoziiert. Den HER-2 Status bestimmt man derzeit durch ein immunhistochemisches 
(IHC) Verfahren oder die fluoreszierende In-Situ–Hybridisierung (FISH). Die Untersuchung des KRAS 
und BRAF Gen-Status erfolgt mittels DNA-Sequenzierung. Aus klinischer und ökonomischer Sicht ist 
es unumgänglich, jene Patienten zu ermitteln, welche tatsächlich von den Gentechnik-basierten, 
teuren Krebsbehandlungen profitieren können. Gesundheitsökonomische Daten zum Gebrauch von 
prädiktiven Tests für HER-2, KRAS oder BRAF sind begrenzt oder gänzlich fehlend.  
Die vorliegende Arbeit untersuchte die Kosten-Effizienz von verschiedenen Teststrategien zur HER-2 
Bestimmung bei der adjuvanten Antikörper–basierten Therapie von Brustkrebspatientinnen. Zusätzlich 
wurden Kosten und Nutzen der Mutationsanalysen von KRAS und BRAF bei therapierefraktären und 
metastasierten kolorektalen Karzinomen aus der Perspektive des Schweizer Gesundheitssystems 
untersucht. Schlussendlich wurden publizierte pharmakoökonomische Studien zu 
Therapiemöglichkeiten bei metastasiertem Brustkrebs kritisch bewertet.  
Methodik. Ein Markov-Modell mit lebenslangem Zeithorizont wurde erarbeitet, um die Kosten 
(ausgedrückt in !) und den Nutzen (ausgedrückt in gewonnenen qualitätsadjustierten Lebensjahren, 
QALY) von prädiktiven Tests bei einer hypothetischen Kohorte von Brustkrebspatientinnen und 
Patienten mit metastasierendem Kolorektalkarzinom zu ermitteln. Das erste Modell verglich 
verschiedene Strategien der HER-2-Testung bei Brustkrebspatientinnen (IHC, FISH, IHC kombiniert 
mit FISH, oder Bestätigung der IHC-2+ Ergebnisse durch FISH). Das zweite gesundheitsökonomische 
Modell untersuchte prädiktive Tests bei Patienten mit kolorektalem Karzinom (KRAS Mutations-
Analyse, zusätzliche BRAF Mutations-Analyse aller Patienten mit KRAS-Wildtyp (KRAS/BRAF), 
Cetuximab-Therapie ohne Testung). Als Referenz-Strategie dienten die Kosten und Effekte, welche 
aus einer Therapie ohne Trastuzumab beziehungsweise Cetuximab resultieren würden. Für den 
Übersichtsartikel wurden publizierte Kosten-Effektivitäts-Analysen (cost-effectiveness) und Kosten-
Nutzwert-Analysen (cost-utility) zu verschiedenen Therapieverfahren bei Patientinnen mit 
metastasierendem Brustkrebs ermittelt und evaluiert. Einerseits wurden die berichteten inkrementalen 
Kosten-Effektivitäts-Verhältnisse, anderseits die Qualität und die zentralen Modell-Parameter der 
gesundheitsökonomischen Studien kritisch bewertet.  
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Ergebnisse. In der Studie zur HER-2-Testung von Patientinnen mit metastasiertem Brustkrebs war 
eine alleinige FISH Testung die kosteneffizienteste Strategie. Sie wies ein inkrementales Kosten-
Effizienz-Verhältnis (incremental cost-effectiveness ratio, ICER) von ! 12‘245 pro gewonnenem QALY 
auf, verglichen mit der Referenzstrategie (kein Trastuzumab). Die zweite Analyse favorisierte die 
kombinierte KRAS/BRAF-Testung. Das ICER betrug ! 67’779 pro gewonnenem QALY, relativ zur 
Strategie ohne Cetuximab. Die Resultate der Basisanalyse blieben auch bei der Durchführung von 
deterministischen und probabilistischen Sensitivitätsanalysen stabil. Die in der Übersichtsarbeit 
identifizierten pharmakoökonomischen Analysen zur Behandlung des fortgeschrittenen 
Mammakarzinoms zeigten sehr unterschiedliche Resultate. Aus klinischer Sicht ergab sich keine 
Präferenz für eine Behandlung mit einer spezifischen konventionellen Chemotherapie. Grundsätzlich 
waren diese Behandlungen meist kostengünstig. Trotz unterschiedlichen gesundheitsökonomischen 
Ergebnissen ist Trastuzumab gegenwärtig der einzige auf ein molekulares Ziel gerichtete monoklonale 
Antikörper, welcher in dieser Indikation angewandt wird.  
Bedeutung. Molekulare Marker mit guter Voraussagekraft, wie z.B. die Überexpression des HER-2-
Proteins, Genamplifikation oder KRAS- und BRAF-Genmutationen, erlauben es zu untersuchen, ob 
Krebspatienten vermutlich auf spezifische, also gegen HER-2 bzw. EGFR gerichtete Therapien 
ansprechen werden. Es zeigte sich, dass beim adjuvanten Mammakarzinom eine alleinige HER-2-
Bestimmung mithilfe von FISH die aus gesundheitsökonomischer Sicht geeignetste Strategie ist. Trotz 
substantieller Kosten der prädiktiven Tests ist es sinnvoll Patenten mit einem fortgeschrittenen 
kolorektalen Karzinom auf ihren KRAS- und BRAF-Status zu untersuchen. Evidenz zur ökonomischen 
Bedeutung der prädiktiven Testung bei Krebspatienten ist gegenwärtig nur begrenzt vorhanden. Mit 
Hilfe von gängigen gesundheitsökonomischen Methoden haben wir versucht, diese Lücke in der 
Literatur kritisch zu beleuchten und teilweise zu füllen, und so wichtige Informationen für Onkologen, 
Pathologen und Gesundheits-Politiker bereitzustellen.  
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Part II - Aims of the thesis 
In an era of rising costs in cancer health care, it has become a necessity to allocate resources as 
efficiently as possible. Predictive testing helps to select the treatments patients will benefit most from. 
Additional costs of novel predictive tests in cancer patients have to be balanced against cost savings 
associated with avoiding treatment of patients who will predictably not respond to antibody treatment. 
However, there is no clear consensus on the most appropriate testing approach. In addition, only 
limited data on the economic consequences of assessing for markers like HER-2 or KRAS/BRAF is 
currently available. Therefore, the outline of this work was to: 
1. Assess the costs and benefits of predictive testing for early breast cancer patients from a 
Swiss health care perspective. By using a life-long Markov state transition model, we 
determined the health economic influence of different HER-2 test assays prior to trastuzumab 
treatment: IHC alone, FISH alone, both tests combined or FISH confirmation of IHC-2+ status. 
Trastuzumab without predictive tests served as reference strategy.  
 
2. Evaluate and summarise results of published, original cost-effectiveness analyses of cytotoxic 
and targeted non-chemotherapy regimens for metastatic breast cancer patients. In addition, 
the quality of reports, methodological and modelling issues will be broadly discussed.! 
 
3. Identify the costs and treatment related effects of predictive testing of chemorefractory 
metastatic colorectal cancer patients. The Markov model determined the pharmacoeconomics 
of the following test strategies prior to cetuximab treatment: KRAS testing alone, KRAS with 
subsequent BRAF testing of KRAS wild-types, and cetuximab treatment without testing.  
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Part III - Introduction 
1. Essentials of pharmacoeconomic evaluations 
1.1. Introduction 
In health care as well as beyond, resources (time, facilities, equipment, money, knowledge) are 
scarce. Hence, choices have to be made. Informed decisions on whether resources should be spent 
for one or the other intervention, should be based on systematic analyses to identify the most 
appropriate alternatives. In the era of increasing health care costs, it is of uttermost importance to 
analyse and discuss the economic consequences of medical services. Health economics strives to 
find out which health services should be provided and consumed by whom. Key determinants are  
• The efficiency of allocation, meaning the determination of the coverage and composition of the 
health care services;  
• The efficiency of production, meaning the choice of the best available method to produce 
health care services;  
• The realisation of the health service allocation at the lowest possible economic expenditures1 2.  
In view of the scarcity of resources, therapeutic, diagnostic and preventive processes are not only 
evaluated with regard to their effectiveness, but also to their economic characteristics, i.e. the ratio 
between resources utilised and associated effects. Health economic evaluation is a sub-discipline of 
health economics and mainly deals with the allocation of resources in the health sector. It is a scientific 
discipline that compares the value for money of one medical strategy to another. This is relevant for 
decisions on which services should be produced in response to different health problems, what kinds 
of interventions are needed to produce a certain level of health outcomes and who should finally be 
offered these services3 4. Several types of health economic studies can be distinguished. Study types 
and concepts used in economic evaluation are described in more detail in the following chapters. 
Pharmacoeconomic evaluations determine the costs and effects of pharmaceutical interventions and I 
hereafter refer to all pharmaceutical-related health economic studies as “pharmacoeconomic 
evaluations”2 3 5. The use and success of a pharmaceutical is, at least in part, constrained by the result 
of pharmacoeconomic evaluations. In addition, pharmacoeconomic studies may help to evaluate 
research projects, to be used as a strategic marketing instrument, to discuss drug price cuttings or, to 
a lower extent, influence reimbursement decisions3.  
1.2. Basic concepts and terminology 
The notion of opportunity cost plays a crucial part in ensuring that scarce resources are used 
efficiently6. Opportunity cost is the cost related to forgone value of the next best choice available to 
someone who has picked between several mutually exclusive choices7. It has been described as 
expressing "the basic relationship between scarcity and choice"8. Hence, the true cost of an 
intervention is what is given up to achieve it. Opportunity costs are not restricted to monetary or 
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financial costs: the real cost of output forgone, lost time, pleasure or any other benefit that provides 
utility should also be considered as opportunity costs9 10. In the health care setting, this approach 
demands for analysing the health gain yielded if resources are invested in the one or the other medical 
intervention. This means that resources saved by one intervention can be invested into another health 
care setting5.  
Health economic evaluations take into account both inputs (costs; expressed in monetary terms) and 
outputs (consequences; expressed in terms of monetary value or clinical efficacy) by generating, if 
applicable, an index of a cost-outcome ratio. Clinical efficacy is ideally expressed as quality-adjusted 
life-years (QALYs), a measure combining integration of survival and quality of life differences1. The 
approach of the study may be of prospective or retrospective nature. 
Hereafter, key basic concepts of relevance for pharmacoeconomic evaluations are discussed.  
1.2.1. Perspective of the evaluation  
Given that medical services are mostly financed by several sources, the perspective of the analysis 
plays an important role. The appraisal of medical resources and hence the outcome of the study is 
mainly influenced by the chosen point of view. In the United Kingdom (UK) e.g., economic studies are 
conducted from the national health system (NHS) perspective which imply to assess how scarce 
resources may be allocated to maximise the health benefit within the NHS’s budget. Evaluations from 
the social perspective include also costs or benefits other than the health care services which may 
occur from a medical intervention (Table 1)11 12. Hence, direct but also indirect costs are included. 
Direct costs covering medical (e.g. costs for health care service, medical staff salaries, drug costs, 
diagnostic tests, treating side effects and complications) and non-medical costs (costs for patient 
transportation, child care or home care service). On the other hand, indirect costs represent loss of 
added value as e.g. loss of productivity, loss of income, loss of leisure time or travel-costs to the 
hospital. Intangible effects (e.g. disease related pain and sufferings) are difficult to value in monetary 
terms. They impact, however, the patients’ quality of life and are implicitly taken into account in the 
denominator of the cost-effectiveness equation if clinical effect is expressed in QALYs3 5 13. 
Evaluations may also take the perspective of the employer or the health insurance (covered services). 
The perspective of the studies has to be clearly stated. The choice of the perspective for 
pharmacoeconomic evaluations is given in some countries by binding recommendations3.  
 Patient  Physician  Hospital  Payer*  Society**  
Direct medical costs  
Physician time  Yes  Yes  Yes  Yes  Yes  
Other medical personnel time (e.g. 
nurse, technician)  
No  Yes  Yes  Yes  Yes  
Drugs  Yes  No  Yes  Yes  Yes  
Medical devices  No  No  Yes  Yes  Yes  
Laboratory tests  No  No  Yes  Yes  Yes  
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Direct non-medical costs 
Administration  No  No  Yes  Yes  Yes  
Physical facility  No  No  Yes  No  Yes  
Patient’s travel costs  Yes  No  No  No  Yes  
Temporary hired care-giver  Yes  No  No  No  Yes  
Indirect costs 
Time off from work to visit physician  Yes  No  No  No  Yes  
Time off work while ill and recuperating  Yes  No  No  No  Yes  
Hire temporary household help while ill  Yes  No  No  No  Yes  
*Third-party payer who reimburses physician for services rendered that are covered by an insurance scheme (private or public). **Sum of all perspectives.  
Table 1. Costs included by using various perspectives. Adapted from Meltzer MI, Lancet, 2001.  
1.2.2. The concept of marginal and incremental costs 
Given that increased usage of medical interventions implies a decreasing marginal benefit, economic 
evaluation is a form of marginal cost analysis. Marginal costs are defined as changes in the total costs 
for producing an increase or decrease of one unit of a good or service. Pharmacoeconomic 
evaluations assess the difference in cost per difference in effect (incremental cost-effectiveness ratio; 
ICER). In other words, this form of analysis assesses the additional costs for producing a further unit 
of clinical effect, which meets the definition of marginal costs3. It should be noted, that the terms 
incremental and marginal costs unfortunately are sometimes used inconsistently in the literature. 
1.2.3. The concept of discounting 
Comparing different medical interventions often implies that costs and effects accumulate at diverse 
points in time. Frequently, the benefit of investing into a medical programme is only realised in the 
future12 14 15. Hence, future costs and health gains are weighted at a lower value than present ones16. 
The discounting of monetary values to the net present value of an investment leads to an economic 
tenable conclusion. Currently, most recommendations include annual discount rates between 3% and 
6%, whereas 5% is the most common rate per year found in the literature17. The extent of how future 
costs and benefits are discounted in economic evaluations remains controversial. In order to assess 
the sensitivity of the obtained results, it is most reasonable to present the data discounted with 
different rates3 5. 
1.2.4. Time horizon 
In a simulation model, the choice of the time horizon is regulated by the research question. It can 
range between a few weeks and numerous years to assess e.g. life expectancy. The time horizon 
should be at least long enough to cover all clinical effects and resource consumption of the studied 
alternatives, i.e. life-long when the disease is chronic or life-threatening17.  
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1.3. Measuring health outcome  
1.3.1. Assessing survival times 
One possibility to measure the efficacy of a treatment in a clinical trial is by determining survival times. 
Usually, it is not possible to observe all patients until they die in a clinical study. Hence, the median 
overall survival is often the primary endpoint in clinical trials. The survival time is usually right-
censored with few patients surviving much longer than the rest18. There are different methods 
available to evaluate the time to an event18 19.  
1.3.2. Utilities as a measurement of health outcome 
Utilities are preference-based measurements of quality of life. Quality of life is expressed on a linear 
scale from zero to one, where the value one stands for perfect health and zero for death1 20 21. They 
are a form of evaluation which focuses mainly on the quality of health outcome gained or averted by 
health interventions. Utility values were developed as a tool for incorporating and rating multiple 
outcomes. This allows comparison of different diseases and health states and serves as a common 
denominator in health economic studies. The effectiveness of a treatment is converted to one common 
measurement unit, i.e. quality-adjusted life-year (QALY) gained which is a two-dimensional measure 
based on both life-prolongation (mortality) and quality of life (morbidity) (Figure 1)1. The QALY is 
obtained through weighting the time-span affected by a health outcome by the utility value of the 
resulting health status22. Utility can be regarded as summary measure of all clinical effects except 
survival time. Hence, it covers intangible effects, in a way.  
Direct utility measuring techniques 
include “standard gamble”, “time trade-
off” and “rating scale”. Gamble 
methods, based on game theory, ask 
patients to choose between a gamble 
and a certainty. The gamble 
represents the probability of dying 
because of a medical intervention 
treating e.g. breast cancer, whereas 
the certainty is given by living with the 
disease. The probability of the gamble 
gets varied until the point where 
individuals are indifferent between gamble and certainty1 12. The point of indifference corresponds to 
the patient’s utility.  
By measuring indirect utility values, different subgroups of health states are rated (e.g. social 
opportunity, health perception and physical function). Indirect measurements are used to achieve 
short questionnaires which can be routinely utilised in the clinical setting. Table 2 exemplifies some 
utility values for different health states20 23 24. 
Figure 1. Exemplified figure of measuring QALYs. Area under the curve 
represents quality adjusted life-time.  
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Health state  Utility value  
Healthy  1.00  
Mild angina  0.90  
Colorectal cancer, primary chemotherapy  0.74  
Stable cancer  0.62  
Dialysis inpatient  0.56-0.59  
Small cell lung cancer, 1 course of radiation  0.63  
Depression  0.45  
Progressive cancer  0.41  
Blind or deaf or dumb  0.36  
Terminal cancer  0.16  
Dead  0.00  
Table 2. Utility values of different health states.  
1.4. Study types 
Health economic evaluations can be of comparative or non-comparative nature. Different study types 
are discussed hereafter.  
1.4.1. Cost-analysis  
Cost-analyses are not comparative and usually measure direct costs of a medical intervention. The 
informative value is, however, limited as alternative strategies are lacking and indirect or intangible 
costs are dismissed. Nevertheless, cost-analyses may serve as initial evidence of the direct treatment 
costs of an intervention3. Their key implication is to generate input parameter for cost-effectiveness 
analyses.  
1.4.2. Cost-of-illness analysis  
Cost-of-illness studies are used as non-comparable, descriptive studies. Mostly, they assess direct but 
also indirect and intangible costs of an illness from a social perspective. Cost-of-illness analyses are 
targeted to estimate and reveal the economic total costs of a disease among the population. They give 
no information on how resources should be allocated to achieve gains in health outcomes. However, 
cost-of-illness studies give important information on the burden of disease that can be used as input 
parameters in economic evaluations. “Bottom-up” cost models prospectively accumulate data for each 
disease on an individual patients’ level. In contrast, the “top-down” approach breaks down the total 
expenditures on medical resources into parts attributable to each illness1 25. 
1.4.3. Cost-minimisation analysis 
Cost-minimisation analyses compare the cost of different treatment strategies with no measurable 
differences in health outcome. Depending on the perspective of the study, this type of analysis 
evaluates the direct, indirect and intangible costs which lead to the selection of the treatment strategy 
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with the lowest costs. The main challenge of cost-minimisation analyses is the fact that major clinical 
effects must be shown to be the same for the comparators (Table 3)3 26.  
Study type  Measurement of benefits  Question posed  
Cost minimisation analysis  Benefits found to be equivalent  
Cost effectiveness analysis  Natural units (e.g. life years gained)  
Cost-utility analysis  
Healthy years (e.g. quality-adjusted life-years, 
healthy years equivalents)  
Which is the most efficient way of achieving a 
given goal (or objective)?  
Or  
What is the most efficient way of spending a 
given budget  
Cost-benefit analysis  Monetary terms  
Should a given goal (or objective) be pursued 
to a greater or lesser extent?  
Table 3. Overview of main types of pharmacoeconomic evaluations.  
1.4.4. Cost-effectiveness analysis 
Cost-effectiveness analyses calculate the monetary differences of various alternatives as well as the 
accompanied effects on the health state. Health outcomes may differ in between treatment 
alternatives. The health outcome is assessed e.g., as lives saved, cases treated or years of life saved. 
It is of outermost importance to measure the economic benefit in regard to life years saved for 
interventions which have a direct or indirect impact on the life expectancy. Life expectancy can be 
determined by the help of e.g. Markov models or life tables3.  
The ultimate aim of a cost-effectiveness study is assessing the ratio of the difference in cost to the 
differences in effects. The incremental cost-effectiveness ratio (ICER) compares the incremental 
difference of total costs to the incremental difference in benefits between two interventions (Equation 
1)1: 
(1) 
The ICER provides information on the cost-effectiveness of an alternative treatment mode. Cost-
effectiveness analysis is one type of study, serving as decision support on the allocation of resources 
which supply maximal health gains for a certain sum of resources. When costs and effects of two 
mutually exclusive treatments have to be compared, we can expect four possible results (Table 2)1 27. 
The result, namely costs and benefits, can be summarised using a so-called cost-effectiveness plane 
(Figure 2).  
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Figure 2. Potential results of a pharmacoeconomic evaluation of two different strategies.  
The endpoint of the evaluation is not strictly defined through the treatment strategy but can rather be 
chosen by the researcher conducting the cost-effectiveness analysis. The favourable treatment relies 
on the willingness to pay for an additional health unit. The level of the willingness to pay is based on a 
supposed assessment of the monetary value of health gains among the society. If the ICER falls 
below the willingness to pay then the “new” treatment (treatment under investigation) is cost-effective 
and can be chosen (Figure 2; applied only for quadrant II). If the ICER falls above the willingness to 
pay then the “new” treatment (treatment under investigation) is assumed not to be cost-effective and 
the “old” treatment should be chosen. However, this benchmark only applies if the ICER falls into 
quadrant I (Figure 2). An ICER in quadrant III (negative ICER) implies that the “new” intervention is 
less effective but less costly, which is however, only acceptable provided that the loss of effects is 
minor.  
1.4.5. Cost-benefit analysis 
Cost-benefit analyses are economic measurements of consequences to create average or incremental 
ratios of cost per outcomes. This form of analysis determines both the intervention costs and the 
effects as monetary value of consumed resources and outcome, respectively1. Alternative treatment 
strategies may have complex or non-comparable health outcomes. Hence, this type of analysis allows 
to weigh against alternatives with dissimilar forms of effect measurements by assessing all 
intervention outcomes in monetary means (Table 3)28. Given this, different outcomes are converted 
into one common denominator which integrates all possible effects in a constant, reasonable and 
reliable manner. However, the monetary appraisal of treatment results is highly controversial, which 
makes cost-benefit analyses increasingly uncommon in the field of pharmacoeconomics. Alternatively, 
tools as e.g. willingness to pay or standard gamble techniques may be used to measure the 
individuals’ willingness to pay to achieve an improvement in treating a disease13.  
I  II  
III  IV 
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1.4.6. Cost-utility analysis 
Cost-utility analyses are a special form of cost-effectiveness analyses and accepted as “gold standard” 
among pharmacoeconomic evaluation, especially in Anglo-Saxon countries. Cost-utility analyses 
assess intervention costs in monetary values and health benefit in non-monetary units, namely quality-
adjusted life-years (QALYs). This form of analysis is based on the fact that medical interventions 
influence the life quality of patients. Establishing the correct utility values according to each disease or 
health state is a key element (as described above)1. The outcome of the evaluation is the net cost per 
QALY gained. Hence, different cost-utility analysis results can be compared with each other, as they 
have a shared denominator (Table 3)3.  
1.5. Handling uncertainties 
1.5.1. The concept of sensitivity analyses 
Pharmacoeconomic models are necessarily simplified compared to the complex and dynamic reality. 
However, values and assumptions included in a model are subject to modification and error (e.g. 
prices, costs, resource use)29. Without a suitable reflection on uncertainties, the conclusion of an 
economic evaluation may not be judged as meaningful and robust30 31. Sensitivity analyses have two 
major objectives: investigating uncertainties in parameters as well as analysing different scenarios. 
The gained information allows confidence in recommending a strategy, if the preferred strategy is 
insensitive to parameter alterations. The range of parameter variation should be based on evidence 
and logic17. There are numerous ways of undertaking sensitivity analyses. Three of these have been 
applied in our study programmes and will be addressed in more detail.  
Deterministic one-way sensitivity analysis 
By varying one variable in the model by a certain degree, the impact of the change on the model’s 
result can be evaluated. For example, potentially influential parameters subject to statistical 
uncertainty (e.g. utility values) are varied within their 95% confidence intervals (CIs). The analysis can 
be repeated with different parameters. Consequently, the key parameters with the greatest influence 
on the result of the model can be identified29.  
Probabilistic multi-way sensitivity analysis 
The likelihood that parameters reach a particular value is associated with uncertainty. In multi-way 
sensitivity analyses, several parameters subject to statistical uncertainty may be varied within one 
analysis. Probabilistic sensitivity analyses measure this uncertainty around the base case results by 
using e.g. 10’000 sets of parameter values randomly sampled from appropriate distributions which 
usually reflect the ranges of variation used in deterministic sensitivity analysis (Figure 3). This 
approach is known as second order Monte Carlo simulation29. Probabilistic sensitivity analyses serve 
as an appraisal instrument to measure the overall impact of parameter uncertainty on the results of a 
pharmacoeconomic evaluation.  
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Figure 3. Cost-effectiveness scatter plot. The results of each set of parameter values are plotted on a chart showing the 
incremental cost and incremental effectiveness of the intervention in question. A large spread of the incremental results 
indicates an increased amount of uncertainty. Results with a tighter spread point towards results associated with a higher level 
of confidence.  
Scenario-analyses 
Scenario-analyses evaluate the influence of variations in specific parameters (e.g. the price of an 
intervention). They measure the range of a possible outcome if parameters have a higher or lower 
value. Several parameters may be varied within one analysis (e.g. to assess local characteristics), but 
scenario-analyses are not of probabilistic nature.  
1.6. Collection and analysis of data 
1.6.1. Within trial analysis versus decision analytic simulation 
Pharmacoeconomic evaluations can either be conducted as within (or alongside) trial analysis or as 
decision analytic simulation. Within trial analyses replicate the health economic outcome of a clinical 
study. This means that they comprise of resource usage and of effects of the trial. The length of the 
analysis is the same as the trial itself. However, these assumptions have some shortcomings which 
should be noted. First of all, consequences of therapies mostly extend over a longer period than the 
trial period. Hence, the primary endpoint of a trial does not necessary reflect the required endpoint for 
health economic evaluation, which commonly has a life-long horizon if the decision to be taken may 
have life-long consequences32. In addition to this, the patient recruitment in clinical studies is highly 
selective due to strict inclusion and exclusion criteria. Furthermore, compliance can be assumed to be 
much higher than in daily routine where motivation and patient information may be less active. 
Generally, the number of medical and diagnostic interventions during a clinical trial can be presumed 
to be much higher compared to the standard clinical practice. Hence, all these assumptions do not 
directly represent everyday clinical reality. For validation reasons, clinical studies sometimes favour 
placebo as comparator, although this assessment does not always reflect the standard therapy17 3. 
Placebo, however, is not an option for being used as a comparator in  pharmacoeconomic evaluations, 
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when standard care is available. The choice of the comparator is still an open discussion and needs to 
be determined individually as the case arises. There is no clear answer, whether the most widely used 
or the “gold standard” should be used as an adequate reference1.  
Modelling has become a widely used tool in the economic evaluation of new interventions in the health 
care setting33. Modelling is required when clinical outcomes have to be extrapolated beyond clinical 
trial data, final outcomes of intermediate measures have to be transformed, data from different 
sources have to be used to carry out a decision analysis, or trial or review data have to be utilised to 
reflect the outcome of different clinical settings17 34. Simulation models take advantage of different 
sources of information to obtain data on the epidemiology, costs and effects to simulate different 
treatment strategies over a period of time1. In brief, they simulate the reality in a simplified way as 
unimportant details are omitted but key information is kept. Generally, simulation models are 
developed on the basis of logical and objective appraisal of intervention and outcome and correspond 
to random, evolving processes34. Nevertheless, these models may miss key information seen in the 
real world. Hence, the structure and content of a model has to be justified, revealed and validated 
using a number of methods, e.g. sensitivity analyses35. Most commonly, Markov cohort models, 
individual based simulation models or decision tree models are used for those simulations. Markov 
models and decision tree models will be discussed in greater detail in the following chapter.  
Noteworthy, within trial analyses and modelling are not mutually exclusive evaluation techniques. 
Frequently, both assessments are combined meaning that trial data serve as basic assumptions which 
are modelled beyond what has been observed in a set of direct observations. Furthermore, trial data 
may be corrected or adjusted to achieve a more accurate reference to the clinical routine. 
1.6.2. Decision analysis models 
Decision analysis models serve as a quantitative clinical epidemiology instrument to measure 
supposed risks, benefits, utilities and costs related to the different treatment options. To a certain 
degree, modelling with decision analyses can support, substitute or revoke results obtained from 
clinical trials. Decision analysis models are also used for the economic evaluation of health care 
technologies36.  
 
 
Figure 4. Exemplified decision tree (! Decision node, " probability node) 
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Decision trees 
Decision trees reproduce economical, clinical, therapeutic and diagnostic processes in a simplified 
way3. For example, they start with a decision (e.g. treatment X or treatment Y), and trace out all 
possible pathways and effects (e.g. costs or health benefits) which accumulate over a period of time 
(Figure 4)1 3. In health economic applications, decision trees might give an answer of how money 
should be invested (e.g. in intervention A or intervention B).  
Markov models 
Some diseases are characterised by recurring disease states which indicate the need for modelling 
the dynamic process of a constant risk of disease recurrence1. In this case, Markov models may be 
used. They are time sensitive state transition models which simulate long-term processes (e.g. chronic 
diseases)34. Analyses of Markov models can be classified into two commonly-used methods:  
1. ‘Cohort analysis’ (expected value calculation) 
In a ‘cohort analysis’, the percentage of a hypothetical cohort in a particular state during a cycle is 
multiplied by the costs and effects which are associated with that state. At the beginning, all 
individuals start in the same or in different 
health state (e.g. disease free, regional 
recurrence or progressive disease). During 
each cycle, individuals can be situated in only 
one of the finite sets of mutually exclusive 
states (Figure 5). The time period of a Markov 
model is composed of equal cycles. The 
change from one state to another is defined 
by the transition probabilities of passing into 
that particular state1. For each state, different 
costs and effects are set per cycle a person 
resides in. The final values are summed up 
over all states and cycles which were 
included in the model37. Cohort analyses are 
restricted in the way of their memory. This 
refers to the chance of moving from one health state to another regardless of the patient’s previous 
history34 38 39. This means that moving from one state to another is not regulated by previous states a 
patient may have experienced. This “memoryless” characteristic may, however, be avoided by using 
different techniques (e.g. first order Monte Carlo simulations)34 38. However, in many practical 
situations, cohort analyses provide as much information as Monte Carlo simulations.  
In our programme, the Markov model was constructed based on a cohort analysis.  
2. First order Monte Carlo simulation (discrete event simulations) 
Discrete simulations represent a large number of patients which are followed through the model 
individually by following a randomly varied path based on transition probabilities. The final results are 
average estimates of numerous trials34.  
Figure 5. Exemplified bubble-diagram of a cancer Markov model.  
22 Part III - Introduction 
 
1.7. Assessing quality aspects of health economic studies 
The usage of clinical trial data with poor quality or biased results as well as inadequately designed 
economic models are a major concern in pharmacoeconomic evaluations. Guidelines have been 
established to increase the validity, robustness and reliability of health economic evaluations. To guide 
critical appraisal of health economic studies, a number of checklists were developed17 40. In principle, 
two primary goals are strived for: the risk of bias in the underlying effectiveness study results and the 
methodological quality of the economic evaluation is assessed (Table 4, originally published by 
Drummond et al, BMJ 1996)17 40. In some countries, there are even binding guidelines how such 
studies have to be conducted (e.g. Australia)41. Our analyses have been conducted based upon the 
guidelines by Drummond et al17.  
Study design  The research question is stated  
 The economic importance of the research question is stated  
 The viewpoint(s) of the analysis are clearly stated and justified  
 The rationale for choosing the alternative programmes or interventions compared is stated  
 The alternatives being compared are clearly described  
 The form of economic evaluation used is stated  
 The choice of form of economic evaluation is justified in relation to the questions addressed  
Data collection  The source(s) of effectiveness estimates used are stated  
 Details of the design and results of effectiveness study are given (if based on a single study)  
 
Details of the method of synthesis or meta-analysis of estimates are given (if based on an overview of a number of 
effectiveness studies)  
 The primary outcome measure(s) for the economic evaluation are clearly stated  
 Methods to value health states and other benefits are stated  
 Details of the subjects from whom valuations were obtained are given  
 Productivity changes (if included) are reported separately  
 The relevance of productivity changes to the study question is discussed  
 Quantities of resources are reported separately from their unit costs  
 Methods for the estimation of quantities and unit costs are described  
 Currency and price data are recorded  
 Details of currency of price adjustments for inflation or currency conversion are given  
  Details of any model used are given  
 The choice of model used and the key parameters on which it is based are justified  
Time horizon of costs and benefits is stated  
The discount rate(s) is stated  
Analysis and 
interpretation of 
results  
The choice of rate(s) is justified  
 An explanation is given if costs or benefits are not discounted  
 Details of statistical tests and confidence intervals are given for stochastic data  
 The approach to sensitivity analysis is given  
 The choice of variables for sensitivity analysis is justified  
 The ranges over which the variables are varied are stated  
 Relevant alternatives are compared  
 Incremental analysis is reported  
 Major outcomes are presented in a disaggregated as well as aggregated form  
 The answer to the study question is given  
 Conclusions follow from the data reported  
 Conclusions are accompanied by the appropriate caveats  
Table 4. Checklist for the appraisal of the quality of health economic studies. Adapted from Drummond et al, BMJ, 1996.  
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1.8. Practical use of economic evaluations  
There is an implicit assumption that decision makers should prefer those technologies with the lowest 
costs but the highest gain in effects. Hence, the primary question is how they can most effectively 
spend resources to extend quality-adjusted life-time or an alternative measurement of clinical effect42. 
Given that the choice of an intervention follows the “rational choice” principle and the alternative with 
the maximal benefit or, respectively the minimal cost is chosen. Medical interventions with better 
health outcome at lower costs are evidently accepted. If interventions indicate improved effects at 
higher costs, the decision is less clear and needs further decision support43. It should be taken into 
account that the term “cost-effective” and “cost-savings” may not be used interchangeably. Cost-
saving interventions decrease costs, whereas cost-effective procedures provide an adequately large 
advantage in contrast to their costs, but may not save money44.  
The affordability of health care may be examined by budget-impact analyses, which supply information 
on how a change in the mix of pharmaceuticals will influence the course of health care spending in a 
certain disease. Budget-impact analyses evaluate the financial implications of establishing and 
diffusing medical innovations within an explicit health care setting. They are working in parallel to cost-
effectiveness studies and may be placed complementary to them for guiding the allocation of health 
care resources45.  
1.8.1. Cost-effectiveness thresholds 
In a number of countries, the decision of accepting or rejecting an intervention is based on the 
willingness to pay for a gained unit of health benefit (e.g. measured as QALY). In the Anglo-Saxon 
region cost-utility analyses are regarded as the “gold standard” for health economic evaluations. 
Based on the reimbursement decision and recommendations by national government agencies, cost-
effectiveness thresholds vary between countries. Usually, a medical intervention is considered as 
justified, if it remains below US$ 20’000, US$ 50’000 (! 39’700) or US$ 100’000 (! 79’300) per QALY 
or life year gained (LYG)46. In North America, a threshold of US$ 50’000 per QALY gained is usually 
accepted, although in the real world, for new medical interventions a much higher threshold is mostly 
applied (US$ 100’000/QALY)47. Recently, Braithwaite revealed that cost-effectiveness thresholds of 
US$ 50’000/QALY are not consistent with present resource allocation decisions among the population 
of the United States of America (USA)48. They estimated a social willingness to pay between US$ 
109’000/QALY (! 86’500/QALY) and US$ 297’000/QALY (! 235’600/QALY) when considering the 
impact of health care on quality as well as quantity of life.! In the UK, the decision rule for the 
acceptability of cost-effectiveness studies ranges according to the National Institute of Clinical 
Excellence (NICE) typically between ! 23’322/QALY (£ 20’000/QALY) and ! 34’983/QALY (£ 
30’000/QALY)49 50. Although not legally binding, this threshold has been more or less officially 
communicated. However, the NICE thresholds are stricter than the limits usually accepted in 
Switzerland.!
Cost per LYG and QALY gained are not exchangeable. Usually, costs per QALY indicate higher 
values than costs per LYG do. Moreover, cost-effectiveness varies according to the target population. 
Usually, the cost-effectiveness ratio improves within high-risk groups.  
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1.9. Implication for our cancer models  
1.9.1. Study type 
In cancer patients, the quality of life is of utmost importance with regard to the clinical outcome. 
Different test assay strategies, as applied in our models, may indirectly influence both the mortality 
and morbidity of cancer patients by the treatment strategy chosen. In my case, cost-utility analyses 
have been thus determined as the most appropriate study type to measure the health economic 
impact of applying diverse predictive test approaches in breast and colorectal cancer patients. In 
addition, this type of study is widely used when assessing costs and benefits of new cancer drugs or 
interventions.  
1.9.2. Design characteristics  
The first breast cancer Markov model was created with cycle lengths of one year, as most health 
economic models in the adjuvant breast cancer setting have used a one-year cycle length. The time 
horizon was life-long. This approach ensured that the simulation model included all stages breast 
cancer patients may undergo during their remaining life. Given that the second Markov model covered 
advanced colorectal cancer patients, the selected cycle length was shorter, namely one month. The 
model horizon was life-long also.  
Both Markov models are based on data from randomised clinical trials while especially utility values 
and information on medical resources have been adapted to establish a reference to the clinical 
reality.  
2. The burden of disease of breast and colorectal cancer  
Cancer is the leading cause of death all over the world. According to the World Health Organization 
(WHO), more than 7.6 million deaths were accounted in 2005. Colorectal and breast cancer are one of 
the main types of cancer, leading to around 639’000 and 519’000 deaths per year, respectively51. 
However, overall life expectancy between 1988 and 2000 for cancer patients has improved. Increases 
in survival of 3.6 years and 1.7 years were reported for breast and colorectal cancer, respectively52.  
2.1. Incidence, prevalence and mortality 
2.1.1. Colorectal cancer 
Colorectal cancer is a considerable cause of morbidity and mortality in the Western world including 
Switzerland. In fact, more than 1 million new cases are identified worldwide each year51. The yearly 
average of Swiss incident cases for colorectal cancer (C18-20) is about 4’029 (period 2003-2007), 
while the rate of new cases has risen by a factor of 1.3 during the last thirty years53. This trend was 
also visible in countries outside Switzerland54. The Swiss one-year prevalence is higher for men than 
for females with 2’256 and 1’646, respectively55. Patients in the age group of 50 years and above are 
largely affected by this type of cancer (94% of all cases)53. 
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Initial therapies of early cancer stages often end up in appearance of recurrent local or metastatic 
disease which finally leads to death from colorectal cancer. About 25% of all cancer cases develop 
metastases56 57. However, colorectal cancer-related deaths indicate a falling number58. In Switzerland, 
approximately 1’809 cancer patient die each year53.  
2.1.2. Breast cancer  
During the period of 2001-2004, the number of new breast cancer cases summed up to 21’141 in 
Switzerland. The highest incidence was found in the age group of 50 to 69 years old females 
(10’380)59. In 2002, 1’404 deaths were recorded among Swiss females 55. Due to the augmented 
performance of screenings, however, the incidence of cancer has increased60. In fact, in Switzerland 
the number of new female breast cancer cases has increased by 1.5 between 1993 and 2007 (yearly 
average: 3’460 (1’993-1987) and 5’244 (2003-2007))53.  
Despite the advantages in breast cancer therapies, the metastatic cancer is still not curable 61. But, 
breast cancer mortality rates have decreased in recent years62 63. This fact can be mainly attributed to 
early detection, efficacious surgical procedures and the ameliorated chemotherapeutic or radio-
therapeutic cancer treatments. Early detection is also associated with a high cure rate for early-stage 
cancer patients. 
2.2. Cost-of-illness 
The trend of declining cancer deaths and increasing incidence is a great progress in cancer treatment, 
but has also increased treatment-related expenditures. The increase in health care expenditure 
reflects the raising volume and intensity of the use of services provided to patients64. In cancer care, 
these interventions include screening, diagnostic tests, medication, surgery, radiation therapy and 
secondary, supportive or palliative care65. Cancer drug costs have attracted growing attention due to 
the high prices of new drugs which exceed frequently the cost-effectiveness thresholds66 67. 
Arguments for these high costs may be the risks for development and production taken by the 
pharmaceutical industry and the significant benefit for cancer patients68. In European countries like 
France or Germany, but also in the USA, it is estimated that cancer care expenditures account for 
about 5% of the overall health care costs69. The financial impact of cancer is substantial, not only for 
society, but also for patients and their families64. In fact, 25% of insured American cancer patients 
claim that they spent most or all of their savings for the cancer treatment, while 33% argue they are 
not able to pay the cancer invoice70. For cancer patients, the survival benefit been found to be worth 
around half of the full income. Even patients with a very low salary would pay up to 40% of their entire 
earnings for gains in survival52. 
Life-time costs of cancer patients vary depending on cancer site, stage of diagnosis, age and 
treatment71-74. In the colorectal setting, estimated mean net annual costs range between US$ 5’341 (! 
4'316) and US$ 11’614 (! 9'386) per patient73. For Stage IV patients, the excess lifetime cancer-
related health care costs are higher and represent approximately US$ 30’794 (! 24'885.19) per year71. 
The estimated annual direct and indirect costs account for about US$ 454 million (! 353 million) in 
Switzerland (Table 5)75. The per-patient costs for the initial breast cancer treatment was estimated at 
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US$ 10’813 (! 8'738), for continuing care at US$ 1’084 (! 883) and for terminal care at US$ 17’886 (! 
14'454)74. Nevertheless, direct and indirect costs are dependent on disease stage. Recent numbers 
from a Belgian breast cancer study presented per patient costs of about ! 107’456 over a six year 
period. Indirect costs measured as productivity loss accounted for 89% of the total costs76. In 
Switzerland, colon cancer patients are estimated to lose approximately 263’400 workdays per year 
(Table 5)75. Hence, indirect costs of illness are major cost-drivers. The introduction of new medical 
innovations which help to prevent, identify and treat cancer patients may, therefore, enhance the direct 
cost at short-term, but do also have a main influence in reducing the productivity loss in those patients.  
 Switzerland  Europe* USA  
Breast Cancer (per year)    
Breast cancer incidence  4’954  282’600  210’000  
Cancer related doctor visits  601’200  44.6m  24.4m  
Cancer related hospitalisation  8’300  681’900  337’600  
Cancer related workdays lost  375’750  27.9m  27.9m  
Direct medical costs  US$ 107m  US$ 6’096bn  US$ 4’530bn  
Indirect medical costs  US$ 347m  US$ 23’378bn  US$ 10’775bn  
Colon Cancer (per year)     
Colon cancer incidence  4’418  287’437  165’690  
Cancer related doctor visits  343’500  25.51m  13.97m  
Cancer related hospitalisation  5’800  785’900  155’400  
Cancer related workdays lost  263’400  19.56m  10.71  
Direct medical costs  US$ 204m  US$ 15.129bn  US$ 8.285bn  
Indirect medical costs  US$ 59m  US$ 4.383bn  US$ 2.400bn  
*25 Member States and Switzerland (2006)  
Table 5. Estimated annual burden of breast and colon cancer. Table adapted from Roche Kiosk, http://www.health-
kiosk.ch/cancer.htm.  
3. Predictive markers in oncology  
3.1. Overview 
3.1.1. Predictive versus prognostic markers 
Prognostic and predictive markers have two distinct roles with regard to treatment decisions in cancer 
care. In principle, prognostic markers assess whether a patient needs a treatment, whereas predictive 
markers identify which treatment will be the most appropriate one. Both markers may characterise the 
patient or the nature of the tumour77. Prognostic factors foresee in an objective and independent 
manner the clinical outcome of a patient as e.g. patients at risk of relapse or with an overall bad 
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prognosis. On the other hand, predictive markers intend to forecast how patients may respond to a 
particular treatment agent78. Often, they are linked to tumour sensitivity or resistance to the medical 
intervention. Molecular markers may have both prognostic (e.g. poor overall prognosis) and predictive 
implications (e.g. response to monoclonal antibody treatment), as is the case with HER-277.  
3.1.2. Predictive and prognostic markers in the clinic 
Monoclonal antibodies have raised hope in the treatment of cancer. Deeper knowledge of the 
molecular pathogenesis has prompted the progress of specific targeted therapies, including 
monoclonal antibodies. These agents have been demonstrated to significantly increase the response 
rate, progression free survival time and overall survival. However, targeted therapies do not fit into all 
patient profiles. Among patients not harbouring a particular gene mutation, gene amplification or 
overexpression of proteins, the probability of response to the targeted treatment is minor78. It is crucial 
to identify reliable prognostic factors as well as biological markers which might have the capacity to 
predict the response of a treatment. Diagnostic tests have to assure that specific evaluation criteria are 
achieved. Key requirements for diagnostic and predictive tests are accuracy, reproducibility, precision 
but also low costs79.  
3.2. Human epidermal receptor 2 in breast cancer 
3.2.1. Biology of HER-2 pathway 
Human epidermal growth factor (HER) 2 (HER-2, ErbB2/neu) belongs to the transmembrane receptor 
tyrosine kinases which are involved in controlling cell growth, survival, differentiation and mitigation80 
81. HER-2 is encoded by the ErbB2 gene which is located on the long arm of the human chromosome 
17 ((17q21-q22)82; CEP17). ErbB2 
receptors are monomers composed 
of 1’233 amino acids (185 kD) and 
are mainly expressed in tissues of 
epithelial, mesenchymal and 
neutronal nature83 84. The ErbB sub-
family includes besides HER-2 three 
other receptors, namely HER-1, 
HER-3 and HER-485.  
HER proteins are present at the 
plasma membrane and form a homo-
dimerisation (of two identical 
receptors) or hetero-dimerisation (of 
two different receptors), when bound 
by a ligand. In contrast to other ErbB 
sub-family members, HER-2 is 
capable of signalling constitutively 
without being activated by a ligand86. 
Figure 6. Signalling pathways of human epidermal growth receptor family 
members. Four homologue receptor compose the EGFR family, namely ErbB1 
(EGFR/HER-1), ErbB2 (HER-2/neu), ErbB3 (HER-3), and ErbB4 (HER-4). 
After ligand binding to EGFR, the ErbB receptor gets activated by homo or 
hetero-dimerisation. This process leads to phosphorylation of catalytic 
substrates of key signalling pathways regulating apoptosis, protein synthesis, 
and cellular proliferation (e.g. through MAPK pathway or PI3K/AKT/PTEN 
family). Adapted from Alvarez, R. H. et al. J Clin Oncol; 2010. 
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This procedure induces kinase activation and trans-autophosphorylation of the receptor. With help of 
adaptor proteins, the receptor is connected to several downstream pathways controlling survival and 
proliferation (e.g. through phosphatidylinositol triphosphate kinase (PI3K) and RAS/RAF/mitogen-
activated protein kinase (MAPK)) (Figure 6)84 87.  
3.2.2. HER-2 protein as a molecular target 
It is estimated that HER-2 gene amplification or protein overexpression is found in about 20% to 25% 
of breast cancers88-90. Aberrant HER-2 signalling is linked to an inhibition of apoptotic stimuli through a 
deregulation of the PIK3-kaskade which leads thus to an aggressive tumour with poor clinical 
prognosis86 89 91. In addition to that, HER-2 overexpression is linked to responsiveness to cytotoxic 
chemotherapy but is resistant to tamoxifen antioestrogen therapy92 93. Blocking HER-2 with targeted 
therapies inhibits the activity of those survival pathways and induces cell apoptosis. Therefore, HER-2 
exhibits a convenient molecular target for specific therapies.  
Lapatinib (Tyverb®, GlaxoSmithKline, London, UK) is a small-molecule inhibitor of the tyrosine kinase 
activity of both HER-1 and HER-2 (Figure 6)94. In combination with chemotherapy, lapatinib is effective 
in locally advanced or metastatic HER-2 overexpressing cancer patients87 95. Trastuzumab 
(Herceptin®, Roche, Switzerland) is a monoclonal humanised antibody targeted against the 
extracellular domain of HER-2 (Figure 6). The exact mechanism of the anti-tumour activity of 
trastuzumab is not yet fully understood. However, from preclinical research, it is proposed that 
extracellular (through antibody-depended cellular cytotoxicity) or intracellular actions like the inhibition 
of signal transduction and cell cycle arrest, inhibition of proteolytic cleavage, inhibition of tumour 
angiogenesis or inhibition of DNA damage repair are the mechanism of action86. In HER-2 positive 
breast cancer patients, the treatment with trastuzumab is clearly associated with improved clinical 
outcome in both the invasive and early disease state96-101.  
3.2.3. Testing for HER-2 
Three different test methods to assess the HER-2 status are currently validated and approved by the 
Food and Drug Administration (FDA): immunohistochemistry (IHC), fluorescence in situ hybridisation 
(FISH) and chromogenic in situ hybridisation (CISH)79 102 103. Some emerging HER-2 testing methods 
like HER-2 silver in situ hybridisation (SISH) which detect HER-2 gene and chromosome 17 using a 
standard bright-field microscope or reverse-transcriptase polymerase chain reaction (RT-PCR) for 
HER-2 gene amplification became, however, not yet firmly established in the laboratories of 
pathologists104 105. In our analysis the techniques most frequently used were focused (IHC and FISH).  
Immunohistochemistry  
Immunohistochemistry (IHC) determines the receptor overexpression by measuring the density of 
HER-2 receptors on the tumour cell surface106. HER-2 proteins are stained by HER-2 antibodies and a 
chemical detection method on formalin-fixed, paraffin-embedded (FFPE) tissues. Two 
immunohistochemical assay methods are approved by the FDA (HercepTestTM; DAKO, Carpinteria, 
CA; and Pathway; Ventana Medical Systems, Tucson, AZ). The test result is visible by bright-field 
microscopes and interpreted based on a specially devised scoring system. Both the intensity and the 
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pattern of the membrane staining are taken into account when interpreting the slides (Table 6)107 108. 
Cancer cells with a score of 0-1+ are not qualified e.g. for trastuzumab treatment, whereas patients 
with 3+ tumour cells are eligible for antibody therapy targeted against HER-2. Equivocal results (2+) 
need further assessment by e.g. FISH102. The test result is highly subjected to inter-observer 
variability.  
 
Table 6. Scoring system and pathology of IHC HER-2 testing. IHC, immunohistochemistry; MAb: monoclonal antibody. Figures 
adapted from Hofmann et al, J Clin Pathol, 2008 and Striebel et al, Am J Clin Pathol, 2008.  
Fluorescence in situ hybridisation (FISH) 
Fluorescence in situ hybridisation (FISH) is a method which identifies the HER-2 gene amplification by 
assessing the copy numbers of the HER-2 gene in the nuclei of the cells in combination with the copy 
number of chromosome 17 centromere (CEP17) in FFPE tissues104. The ratio of the number of HER-2 
signals to the number of CEP17 signals in the nuclei of twenty cancer cells yields the FISH test result. 
In HER-2 positive tumour cells, two or more HER-2 gene copies per chromosome 17 have to be found 
(gene amplification) (Table 7)79 107-109. According to the American Society of Clinical Oncology and the 
College of American Pathologists (ASCO-CAP) guidelines, the cut-off ratio for HER-2/CEP17 for 
normal cells is below 1.8 (or less than 4 HER-2 gene copies per nucleus), while HER-2 positivity was 
defined as a HER-2/CEP17-ratio greater than 2.2 (or more than 6 HER-2 gene copy numbers per 
nucleus)79. The range between 1.8 and 2.2 (or 4-6 HER-2 copy numbers per nucleus) was determined 
as equivocal for HER-2 amplification, given 2% of breast cancers fall in this interval79 110 (Table 7). 
Currently, three specific FDA approved FISH-assays are available (PathVysion; Abbott Laboratories, 
Abbott Park, IL; INFORM; Ventana Medical Systems, Tucson, AZ; and PHarmDx; DAKO, Glostrup, 
Denmark). The test results are visible through a fluorescence microscope.  
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FISH testing is a quantitative and objective method but time-consuming and hence, an expensive 
technique. Test results can be influenced by the thickness of the tissue section. The interpretation and 
recognition of the invasive component require experience104.  
 
Table 7. Scoring system and according image for HER-2 assessment by FISH. CEP17, chromosome 17; MAb, monoclonal 
antibody. Figures adapted from Hofmann et al, J Clin Pathol, 2008 and Striebel et al, Am J Clin Pathol, 2008.  
3.2.4. Which test is the most appropriate one? 
Regardless of a long history of HER-2 testing in breast cancers, there is still no consensus what test 
represents the best assessment („gold standard“) of the HER-2 status. Both assay methods have 
technical shortcomings resulting in different sensitivities and specificities. The debate is still ongoing 
regarding what is the best test to assess the HER-2 status, because there are contradictory results 
reported in the literature comparing HER-2 status determined by FISH or IHC assays in FFPE tissues. 
However, standardisation of IHC in FFPE tissue samples is difficult to achieve due to numerous pre-
analytical problems and a high subjectivity in the interpretation of IHC samples. High concordance 
between IHC and FISH tests is achievable, but this is mostly dependent on the methodology, 
instrumentation and experience of the laboratories carrying out the tests111. It was shown that 
concordance rates between IHC and FISH tests range between 80% and 90% and this implies the 
production of significant numbers of false negative tests, which may have a dramatic consequence for 
the affected patients111 112.  
In addition to these primary criteria, secondary considerations, such as costs are helpful in selecting 
different assay strategies. Although the ASCO-CAP guidelines recently recommend IHC assays for 
initial evaluation of the HER-2 status, primary use of FISH in initial testing is also discussed. Higher 
reproducibility and more accurate assessment of the HER-2 status are strong arguments for FISH, but 
31 Part III - Introduction 
 
it has been argued that FISH is more expensive, time consuming and require more expertise than 
IHC113. IHC is limited in terms of conditions of the test procedure including time to fixation, fixation 
duration, processing, denaturation, heating, antigen retrieval, the staining procedure used, and the 
interpretation of staining114. Furthermore, detecting HER-2 overexpression at the protein level may 
imply inadequate conclusions.  
3.3. KRAS and BRAF in colorectal cancer 
3.3.1. Biology of the KRAS/BRAF- pathway 
The activation of EGFR is used by tumour cells as a key element for independent proliferation and cell 
survival. When a ligand binds to the extracellular domain of the receptor, the receptor dimerises and 
triggers its enzymatic activity followed by the phosphorylation of the intracellular domain. Through 
relocalisation to the plasma membrane, cellular effectors bind to the phosphorylated residues of the 
intercellular part and initiate cell growth, development and cell functions115 116. Intracellular key 
mediators of the EGFR signalling include the small G-protein RAS (KRAS), the protein kinase v-raf 
murine sarcoma viral oncogene homolog B1 (BRAF), phosphatidylinositol 3'-kinase (PI3K)/AKT, and 
the JAK-STAT pathway115.  
The initiation of the KRAS protein can induce BRAF protein activation. BRAF has a known role in 
triggering signal transduction through the mitogen-activated protein kinases (MAPK) (Figure 7)115. 
MAPK translocates to the nucleus and induces the expression of genes involved in cell survival117. 
Hence, the pathway through RAS/RAF/MAP has been shown to be highly relevant in the proliferation 
and survival of the cell (Figure 7)115 118. EGFR members of the ErbB receptor family and their effectors 
have been found to be mutated in various cancers, including colorectal cancer119.  
 
Figure 7. Network of interactions of EGFR with downstream signalling pathways in colorectal cancer. Adapted from Harari et al, 
J Clin Oncol, 2007.  
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3.3.2. Monoclonal antibody therapy in metastatic colorectal cancer 
In order to target the molecular and cellular effects of the altered EGFR signalling, monoclonal 
antibodies have been developed to compete with the binding of ligands to the extracellular domain of 
the receptor120. In Switzerland, two monoclonal antibodies have been approved for treating advanced 
colorectal cancer in KRAS wild-type patients: Cetuximab (Erbitux®, Merck AG, Zug, Switzerland) a 
mouse-human chimeric anti-EGFR antibody and panitumumab (Vectibix®, Amgen Europe B.V., 
Netherlands) a fully human monoclonal antibody. Cetuximab has demonstrated clinical efficacy both in 
monotherapy and in combination with irinotecan121 122. Panitumumab has shown clinical benefit in 
terms of progression-free and overall survival when used as single agent123 124. Given that the 
advantage of those agents are largely limited to KRAS wild-type patients, the labels have been 
amended to cover this restriction125 126. 
3.3.3. KRAS mutation 
The KRAS gene encodes for a 21kDa small G-protein127. About 40% of colorectal cancer patients 
reveal a KRAS mutation128-130. Generally, these mutations derive from somatic point-mutations. In 
more than 95% of colorectal cancer cells, KRAS mutations are mainly found in codons 12 and 13 of 
the KRAS-oncogene which cause the constitutive activation of the protein (Figure 8)131-134. Mutations 
in codon 61 are seen less frequently (about 3%)135. Further research is needed to assess whether 
additional codon mutations are involved in the process. Patients harbouring KRAS mutations in codon 
12 or 13 have shown resistance to treatment with EGFR monoclonal antibodies like cetuximab129 136-
138. In addition to the predictive value, KRAS mutation is discussed as a prognostic marker in terms of 
metastatic potential, prognosis, progression-free and overall survival139 140.  
3.3.4. BRAF mutation 
Recent clinical data suggests that KRAS wild-type patients harbouring BRAF mutation do not benefit 
from anti-EGFR therapy133 141. In colorectal cancers, BRAF mutations are found in about 8% to 10% of 
KRAS wild-type cells142 143. Hence, KRAS and BRAF mutations occur in a mutual exclusive manner141. 
The most common BRAF mutation is the V600E (substitution of glutamic acid for valine at position 
600) which leads to constitutive activation of BRAF independent of KRAS signalling (Figure 8)134 144. 
Furthermore, BRAF-V600E mutation is linked to microsatellite instability (MSI)145. Similar to KRAS, 
there is evidence that BRAF may also be used as a prognostic marker146.  
3.3.5. Testing for KRAS/BRAF mutation  
According to the provisional clinical opinion of the ASCO, monoclonal antibody therapies directed 
against EGFR are not indicated if tumour cells of advanced colorectal cancer patients are a carrier of a 
KRAS mutation147. Hence, the genetic mutation analysis for KRAS is mandatory before the treatment 
with cetuximab or panitumumab. For an accurate KRAS testing procedure, the European Society of 
Pathology in collaboration with the European Quality Assurance Council and the ASCO have 
established guideline recommendations116 147. Nevertheless, until now, there is no official KRAS 
testing method and international guidelines for assessing predictive markers are still in process116. 
Testing for BRAF mutation has recently been introduced in some laboratories.  
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There are several methods available to 
detect KRAS and BRAF mutations in solid 
tumours like, e.g., direct DNA sequencing 
allele-specific real-time polymerase chain 
reaction (PCR), analysis of high-resolution 
melting curve, pyrosequencing or others57 134 
148-151. FFPE biological samples serve as 
material for the gene status assessment. 
Most assays identify point mutations in 
tumour samples, nevertheless, not all 
techniques are able to detect rare mutations. 
The results of the mutation analyses are 
mainly influenced by the tumour purity, 
fixation and the procedure of the DNA 
extraction, the selection the protocol of the 
mutation analyses and finally, the reporting of 
the results127 152. Few studies have 
determined the pros and cons of different 
assays, but test results were similar for 
most153-155. Basically, the selection of the test 
approach is laboratory dependent.  
 
Sanger method 
The traditional cycle sequencing reaction on the basis of the Sanger method searches for KRAS point 
mutations in codons 12 and 13156. This method is the “gold standard” for KRAS mutation analysis, also 
in Swiss laboratories (Figure 9)157 134 158. The main features of this approach are the potential to define 
the specific point-mutation and the capacity to identify all possible base substitutions, small insertions 
or deletions154. These assays feature high sensitivity and perfect specificity, hence false negative or 
false positive results are scarce, but cannot be ruled out entirely. The exact sequence and the 
performance of the test by the laboratory primarily determine the test results154.  
Allele-specific PCR 
The assay for an allele-specific PCR requires sequence-specific probes and assesses targeted 
mutations in codons 12 and 13. Hence, only those mutations included in the assay can be identified. 
Due to the selective DNA amplification of mutated alleles only, the PCR based approach is 
characterised with a high test-sensitivity57 153. This method has been applied in several pivotal 
studies124 136 159.  
Figure 8. KRAS and BRAF signal transduction. Ligand-binding (e.g. 
EGF) leads to dimerisation of EGFR-protein and hence to the 
activation of the cytoplasmatic signalling cascade (KRAS-BRAF-
MEK-ERK) which stimulates cell-proliferation and cell–maturation. 
By a mutation in the KRAS or BRAF-gene sequence, KRAS or 
BRAF (asterix) get oncogenic and induce the signalling cascade 
independent of EGFR. This results in strongly enhanced 
proliferation and maturation of the tumour cell. Adapted from Bode 
et al. UZL-News: Ausgabe Nr. 18 (2008).  
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Pyrosequencing 
Pyrosequencing is a bioluminescence 
procedure154. Individual bases or short 
stretches of DNA sequences are identified by 
this technique. Clustered mutations are 
determined with high sensitivity150. In addition 
to this, there is a possibility to execute 
separate assays on the same run160.  
High-resolution melt curve analysis 
Quantitative PCR with melting curves takes 
advantage of different melting temperatures 
due to genetic alterations. Given that mutated 
sequences have less affinity for the wild-type 
DNA probe, they detach at a lower 
temperature than perfectly matched wild-type 
sequences. Fluorescent probes are used to 
detect disparities in the melting curve. False 
positive cases can be found in about 5% and 
additional sequence analyses are needed for 
confirming mutant samples154 153. 
Restriction fragment length polymorphism 
Compared to wild-types, KRAS/BRAF 
mutations cause a variation in cut sites by 
restriction enzymes. The restriction fragment 
length polymorphism is highly sensitive, but 
requires additional sequence analyses in 
mutation-positive cases153.  
 
 
 
Figure 9. KRAS mutation analysis by Sanger. After DNA 
extraction of isolated tumour samples (tumour cell fraction over 
50%), PCR amplification specific for KRAS is carried out. 
Afterwards, the amplification-products are sequenced. Mutations 
are identified by comparisons with the normal sequence. Adapted 
from Bode et al. UZL-News: Ausgabe Nr. 18 (2008). 
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Abstract Trastuzumab has conferred significant clinical
benefits in HER-2-positive breast carcinomas. HER-2 sta-
tus is determined by immunohistochemistry (IHC) and/or
fluorescence in situ hybridisation (FISH), but appropriate
assessment of HER2 status remains subject to considerable
debate. Data on the health economic impact of HER-2 test
strategies are limited. A life-long Markov state transition
model was used to assess costs and effectiveness of HER-2
assay strategies (based on IHC, FISH, both combined or
FISH confirmation of IHC2?) for a hypothetical cohort of
early breast cancer patients from the perspective of the
Swiss health system. We compared clinically relevant
strategies of predictive testing and subsequent trastuzumab
treatment of HER-2-positive patients only. FISH testing
was the most cost–effective strategy with an incremental
cost–effectiveness ratio of €12,245 per additional quality-
adjusted life-year (QALY) gained, compared to no trast-
uzumab treatment. The next best strategy was parallel IHC
and FISH, with costs of €400,154/QALY gained compared
to FISH alone. FISH as primary HER-2 testing modality
remained the preferred option in deterministic and proba-
bilistic sensitivity analysis. Predictive testing to identify
adjuvant breast cancer patients who benefit from trast-
uzumab treatment is a clinical and economic necessity. Our
model identifies FISH as the most cost–effective approach.
Keywords Cost–effectiveness ! Adjuvant !
Breast cancer ! Predictive tests ! Trastuzumab
Introduction
Human epidermal growth factor receptor 2 (HER-2/neu,
hereafter referred to as HER-2), is a transmembrane
receptor tyrosine kinase expressed in epithelial cells
including the breast. Approximately 20–25% of breast
cancers patients show HER-2 protein overexpression and/
or HER-2 oncogene amplification [1–4]. Both are markers
for aggressive disease [5, 6] and the molecular targets of
trastuzumab (Herceptin", Roche Pharma, Switzerland) and
lapatinib (GlaxoSmithKline, London, UK). Trastuzumab, a
humanized monoclonal antibody, is used successfully in
the therapy of HER-2-positive invasive breast carcinomas
[7–10]. In the adjuvant setting, it substantially reduces
recurrence rates and overall mortality in combination with
chemotherapy [11–14]. There is now consensus on a life-
prolonging effect in metastatic, early node-positive and
node-negative HER-2 positive invasive breast cancers.
Trastuzumab has also dramatically increased treatment
costs [15].
Gene amplification and protein overexpression can be
identified by immunohistochemistry (IHC) or fluorescence
in situ hybridisation (FISH), respectively [7]. Despite a
long history of predictive HER-2 testing in breast cancer
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patients, there is still no consensus on the most appropriate
testing approach. Selection criteria include accuracy,
reproducibility and precision but also cost [16]. Published
results comparing HER-2 status determined by FISH or
IHC in formalin fixed, paraffin embedded (FFPE) tissues
are contradictory. Standardization of IHC in FFPE tissue
samples is difficult due to pre-analytical problems and high
subjectivity in interpretation. Concordance rates range
between 80 and 90%, depending on the methodology,
instrumentation and experience of the laboratories carrying
out the tests [17]. This implies significant numbers of false
negative test results, which may have dramatic conse-
quences for the affected patients [18]. Current American
Society of Clinical Oncology and the College of American
Pathologists (ASCO-CAP) guidelines recommend the use
of IHC for initial evaluation of HER-2 status but initial use
of FISH is also discussed [19]. Arguments for FISH include
better reproducibility and accuracy, although FISH is more
expensive than IHC [20].
Expensive new cancer therapies are usually regarded as
appropriate if trial data show clinically relevant improve-
ments [21, 22]. Several publications have addressed the
cost–effectiveness of trastuzumab in HER-2-positive breast
cancer patients [23–25]. Markov models have been used to
evaluate the cost–effectiveness of HER-2 testing strategies
in the adjuvant and metastatic settings [26–28] but com-
prehensive cost–effectiveness analysis comparing alterna-
tive assay strategies are limited.
Using a life-long Markov state transition model, we
evaluated the health economic impact of trastuzumab
treatment of adjuvant breast cancer in Switzerland and the
influence of different HER-2-testing strategies (IHC, FISH,
both combined or FISH confirmation of IHC2? status)
[29]. The model can also be used for similar decision
problems arising with other predictive tests in pathology.
Methodology
Overview of breast cancer disease model
A Markov model with a cycle length of 1 year was used to
reproduce the disease process and economic consequences.
Economic endpoints were the costs associated with each
strategy. Effectiveness was assessed as quality-adjusted
life-years (QALYs). Incremental cost–effectiveness ratios
(ICERs) were planned to be calculated if applicable, i.e. in
non-dominant situations. The time horizon of the analysis
was life-long (50 years).
Costs were assessed from the perspective of the Swiss
health care system. Consequently, non-medical and indi-
rect costs were disregarded. Direct medical costs included
drug costs, costs for predictive testing (where applicable),
gynaecological examinations, diagnostic procedures and
hospitalization (Table 3). Costs and effects were dis-
counted at 3% [21]. Costs are shown in Euros (€). In March
2009, €1.00 equalled Swiss Francs (CHF) 1.50.
Patient populations studied
The model assessed a hypothetical cohort of female
breast cancer patients aged 50 years, of whom 20% were
HER-2-positive. The HER-2-positive patient population
was defined by the eligibility criteria of the HERA trial
[12]. In brief, patients had centrally validated HER-2-
positive early stage invasive breast cancer with either
node-positive or node-negative disease status (disease-free
status). They completed local regional therapy and at
least four courses of predefined standard adjuvant or
neoadjuvant chemotherapy. Eligibility criteria for disease-
free HER-2-negative patients were WHO performance
status 0–1 with a confirmed HER-2-negative status. They
had undergone breast surgery with axillary-node dissec-
tion or sentinel-node biopsy for invasive breast carcinoma
[11].
Strategies compared
We assessed the following testing strategies: IHC alone,
FISH alone, parallel IHC and FISH, sequential testing
with FISH confirmation of IHC2?. Patients with positive
IHC (2? or 3?) and/or positive FISH received adjuvant
trastuzumab treatment. Patients with no or a very low
HER-2 expression levels (IHC 0 or 1? or negative FISH)
received standard treatment. Costs and effects of no
trastuzumab treatment and a strategy of trastuzumab
treatment of all patients with no predictive testing were
used as reference values. The latter does not represent a
clinically relevant option but was added to demonstrate
the overall magnitude of the benefits achieved with pre-
dictive testing.
False positive and false negative test results lead to
inadequate treatment of the affected patients. Sensitivity
and specificity of IHC and FISH was assessed from pub-
lished literature [30]. Sensitivity and specificity of the
parallel testing strategy were calculated according to the
‘‘believe-the-positive’’ approach, i.e. the combined result
was positive if one test indicated a positive result. Both
tests were regarded as conditional independent (Table 1)
[31].
Disease stages
The simulated population moved through distinct disease
states, namely, disease-free survival, local recurrence,
regional recurrence, metastatic disease and death (Fig. 1).
Breast Cancer Res Treat
123
Local recurrence was defined according to the American
Joint Committee on Cancer (AJCC) as isolated ipsilateral
in-breast cancer recurrence after breast-conserving therapy
of a stage 0–III breast carcinoma [32]. Regional recurrence
included patients with cancer recurrence in the axilla with
or without in-breast recurrence after breast-conserving
therapy of stage 0–II breast carcinoma [33]. Metastatic
disease implied women with progressive metastatic breast
cancer without previous chemotherapy treatment for met-
astatic disease [7].
Clinical data sources
Clinical model inputs, namely, state transition probabilities
for patients with HER-2-positive and HER-2-negative
breast carcinomas (Table 2), were derived from the liter-
ature. We disregarded phase II trials, studies only presented
as conference abstracts, studies with very low sample size,
and studies with insufficient information for being used in
our model. Efficacy results from studies of monoclonal
antibodies targeted against HER-2 other than trastuzumab
were not taken into account. Modelling of disease-free
survival was based on HERA [12]. We assumed that HER-
2-positive individuals with trastuzumab treatment would
have the same transition probabilities as the patients
receiving adjuvant trastuzumab in HERA. The recurrence
rates seen in the HERA comparator group were applied to
our HER-2-positive group without trastuzumab treatment.
In the HER-2-negative situation, transition probabilities
were assumed to be unaffected by trastuzumab treatment
[11].
The future history of patients entering the local and
regional recurrence states was derived from published
retrospective reviews of medical records and was not
dependent on HER-2 status [34, 35]. One-year survival
rates in metastatic breast cancer patients stemmed from two
phase III trials of standard treatment plus trastuzumab
versus best supportive care [7, 36]. It was assumed that
after 5 years, the risk of reappearing metastasis would
decline by 10% annually [37].
Overall mortality rates of the Swiss female population
was taken from published Swiss life tables [38].
Utilities
Utilities were based on a study using the self-administered
EQ-5D questionnaire [39]. Responses were combined with
Table 1 Testing strategies and test characteristics
Test strategy Test Cut-off for HER-2 positivity Sensitivity (±95% CI) Specificity (±95% CI) Ref.
1. All IHC 2? and 3? 0.91 (0.88–0.94) 0.75 (0.72–0.77) [30]
2. All FISH C2.0b 0.98 (0.87–1.0) 0.9 (0.82–0.95) [30]
3. All, parallel testinga IHC 2? and 3? 0.9982 (0.9844–1.0) 0.675 (0.5904–0.7515) [30, 31]
FISHa C2.0b
4. First all IHC 3? 0.905 (0.893–0.933) 0.987 (0.976–0.992) [17]
Second: If IHC2? FISH C2.0b
5. No test, all trastuzumab
6. No test, no trastuzumabc
NB: sensitivity and specificity of the combined tests remain in sequential or parallel testing order the same [58]
a BTP belief the positive. 1 positive test is enough for ? results. Negative result if both test -
b Ratio HER-2/CEP17 signal
c Reference strategy
Fig. 1 Markov model starting with the disease-free health state.
Diagram of model structure, comprising five health states: disease
free, local recurrence, regional recurrence, metastasis (distant recur-
rence) and death
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visual analogue scale-based population preference values.
Utilities per disease stage were: first year after primary
breast cancer, 0.696 (95% confidence interval (CI) 0.634–
0.725); first year after recurrence, 0.779 (CI 0.700–0.849);
second and subsequent years after primary breast cancer/
recurrence, 0.779 (CI 0.745–0.811); metastatic disease
state, 0.685 (CI 0.620–0.735) [39].
Medical resource use
HER-2-positive group
Disease-free status
HER-2-positive patients received trastuzumab after exci-
sion of early stage breast cancer and completion of che-
motherapy. Trastuzumab dosing and planned treatment
duration corresponded to the regimen used in HERA, with
a 8 mg/kg loading dose and 6 mg/kg dose every 3 weeks
during 1 year [12]. We assumed that 15% of the patients
would receive an additional 150 mg vial due to higher
weight ([74 kg). Echocardiography was performed quar-
terly during trastuzumab treatment [12]. All patients
received gynaecological examinations [40]. During
5 years, half of HER-2-positive patients were treated with
aromatase inhibitors (letrozol 2.5 mg/day or anastrozol
1 mg/day) [12].
Local and regional recurrence
Mammography, gynaecological examinations, diagnostic
ultrasound, radiotherapy and surgery including hospitalization,
and aromatase inhibitors (as described above) were used in
these patients [25]. Local recurrence was assumed to be
localized in the thoracic wall (40%) or in the breast (60%) [41].
Metastatic state
Chemotherapy, radiotherapy, diagnostic ultrasound and
palliative surgery including hospitalization, and aromatase
inhibitors (as described above) were used in these patients
[25]. We assumed that 80% of the patients responded to
trastuzumab treatment in the first-line therapy and that half
of these patients were re-treated with trastuzumab for an
additional year when metastases were diagnosed [7].
Untested group
Untested patients all received trastuzumab treatment as
described for the HER-2-positive group. Aromatase
inhibitor was given to 70% of these patients for 5 years
[12, 42, 43].
HER-2-negative group
Patients with no HER-2 overexpression did not receive
trastuzumab but were otherwise treated as described for the
HER-2-positive group. During 5 years, 70% were assumed
to receive hormone therapy [42, 43].
Unit costs
Unit costs (Table 3) for laboratory and diagnostic inter-
ventions were derived from the official Swiss tariff list
[44]. Hospital case-based flat rates and day rates were
Table 2 Annual transition probabilities
HER-2 status Trastuzumab ? Yes ? No - Yes - No Ref.
Disease state Transition to
Disease free Disease free 0.934 0.879 0.975 0.975 [11, 12, 59]
Local recurrence 0.01 0.022 0.004 0.004
Regional recurrence 0.006 0.008 0.004 0.004
Metastatic diseasea 0.05 0.091 0.017 0.017
Local recurrence Disease free 0.878 0.878 0.878 0.878 [35]
Local recurrence 0.028 0.028 0.028 0.028
Metastatic diseasea 0.094 0.094 0.094 0.094
Regional recurrence Disease free 0.895 0.895 0.895 0.895 [34]
Metastatic diseasea 0.105 0.105 0.105 0.105
Metastatic disease Metastatic diseasea 0.78 0.67 0.788 0.788 [7, 36]
Death 0.22 0.33 0.212 0.212
a Transition probabilities only shown for first 5 years. In the subsequent cycles, the model assumed a declined recurrence rate of 10% after each
cycle
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based on Swiss Diagnosis Related Groups (DRGs) [45].
Length of hospital stay was based on data provided by the
Swiss Federal Statistic Office [46]. Drug costs based on
official Swiss pharmacy prices [47]. Costs of diagnostics
and therapeutic interventions in each state were assessed on
this basis. However, as the adjuvant therapy was assumed
to be the same for all patients, costs of initial treatment
(primary breast surgery and adjuvant chemotherapy) were
not included.
Sensitivity analysis
Deterministic sensitivity analysis tested the precision and
robustness of the results. Parameters with a direct impact
on incremental costs were varied by ±30% (price of
trastuzumab, price of predictive tests, costs of local and
regional recurrence and metastatic disease). Medical
resource use was not varied separately as it was assumed
that any related uncertainty would be covered by the var-
iation of unit costs. The discount rate was set to 0 and 6%.
In addition, variables subject to statistical uncertainty
(sensitivity and specificity of IHC and FISH, metastatic,
local and regional recurrence rates, utilities) were varied
within their 95% confidence intervals (CIs) [48]. The
prevalence of a normal (negative) HER-2 expression pat-
tern was varied between 75 and 85%.
Probabilistic sensitivity analysis
Uncertainty around the base case results was additionally
assessed by probabilistic sensitivity analysis (PSA), using
10,000 sets of parameter values randomly sampled from
beta distributions reflecting the ranges of variation used in
deterministic sensitivity analysis [49]. Parameters covered
included HER-2 prevalence, utilities, transition probabili-
ties, and test sensitivity and specificity. Unit costs were not
subject to uncertainty and therefore not included in the
PSA [44].
Model implementation
The Markov model was implemented in TreeAge Pro!
2009 (TreeAge Software Inc, Williamstown, MA, USA).
Table 3 Cost per type of resource use (per first year in € per patient)
Type of resource Duration/amount Unit cost (€) Ref.
Hormonal therapy 1 year 2,233 [44, 47]
Trastuzumab price (Herceptin!, Roche, Switzerland) 1 vial per 150 mg 860 [47]
1 vial per 440 mg 2,341
Trastuzumab treatment (Incl. Infusion and 49 echocardiography) 1 year 42,588 [44, 47]
IHC test 1 test 53 [44]
FISH testa 2 test probes 686 [44]
Gynaecological examinationb 1 142 [44]
Mammography 1 107 [44]
Sonography 1 year 100 [44]
Surgery 1 year 1,275c [44]
2,778d
Material 1 year 167 [44]
Anaesthesia 1 year 540 [44]
Radiotherapy 1 year 4,688e [44]
8,467f
Hospitalization 7.6 days 2,281g [60]
a Based on the resource use in Swiss laboratories
b According to the Swiss Consortium for Gynaecological Oncology and Obstetrics (AGO) [40]: four examinations per year in the years 1–3, two
examinations in the years 4–5, one examination in the years 5–10 and biennial examinations thereafter
c Local recurrence in the breast
d Thoracic local recurrence and regional recurrence
e For thoracic local recurrence
f For regional recurrence
g Average duration of stay of C500 to C509 (ICD10 classification) during 2005 in Switzerland
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Results
Base case analysis
Effect
Differences in effectiveness between the strategies
involving trastuzumab treatment arose from imperfect
sensitivity and specificity of the testing strategies
(Table 1). Some HER-2-positive patients had false nega-
tive test results and hence did not receive trastuzumab,
which lead to a loss of QALYs. Therefore, the no testing
strategy (where all patients received trastuzumab) accrued
most QALYs (12.751 QALYs per patient). The testing
strategies accrued between 12.741 and 12.750 QALYs. At
the lower end, the no trastuzumab strategy resulted in
12.254 QALYs (Table 4).
Costs
Trastuzumab substantially increased costs in both the
testing and non-testing strategies, compared to no trast-
uzumab treatment. However, the increase was distinctly
lower in the testing strategies. Here, trastuzumab costs
were strongly reduced as therapy was targeted to those
patients who profited most (Table 4).
Per-patient total lifetime costs in the predictive testing
strategies ranged from €38,153 (FISH confirmation of
IHC2?) to €41,830 (parallel IHC and FISH). FISH con-
firmation of IHC2? saved €62 in comparison to FISH
alone. If FISH alone was used, per-patient savings
compared to IHC alone and parallel IHC and FISH would
be €1,736 and €3,615, respectively.
Incremental cost–effectiveness
The reference (no trastuzumab) strategy was least costly
and least effective (€32,258 and 12.254 QALYs per
patient) (Table 4). FISH alone testing was associated with
a per-patient cost of €38,215 and resulted in 12.741 QA-
LYs, corresponding to an ICER of €12,245/QALY when
compared with the no trastuzumab strategy. This was the
most favourable ICER observed. FISH alone testing dom-
inated IHC alone and FISH confirmation of IHC2?. In the
latter comparison, FISH alone was in a situation of
extended dominance [50], e.g.it was slightly more expen-
sive but showed a better incremental cost–effectiveness
ratio than the comparator. Superior characteristics of the
FISH test lead to a gain in clinical effectiveness and hence,
clinical savings that over-compensated or near-compen-
sated much higher test costs. The ICER of parallel IHC and
FISH was €400,154/QALY compared to FISH alone.
ICERs for the non-testing approach were prohibitively
high. Figure 2 summarizes cost–effectiveness results.
Current Swiss data show an annual average of 5,091
incident breast cancer cases between 2001 and 2005 [51].
On this basis, FISH confirmation of IHC2? versus FISH
alone would lead to cost savings of €315,642, and lose 245
QALYs, per year. FISH alone compared to IHC alone
would save €8,837,976, and gain 177 QALYs, per year.
FISH alone compared to parallel IHC and FISH would lead
to savings of €18,403,965 and a loss of 46 QALYs.
Table 4 Base case cost–effectiveness analysis (CEA) of different testing strategies (reference: no trastuzumab)
Test strategy Lifetime cost
per person
Lifetime
efficacy
C/E Incremental
costsa
Incremental
efficacyb
ICER
Unit € QALY €/QALY € QALY €/QALY
No trastuzumabc 32,258 12.254 2,632 – – –
IHC first (FISH only for IHC2?) 38,153 12.693 3,006 (5,895)d (0.4384)d Dominatedd
FISH alone 38,215 12.741 2,999 5,957e 0.4865e 12,245e
IHC alone 39,951 12.706 3,144 (1,736)f (-0.0348)f Dominatedf
Parallel IHC and FISH 41,830 12.750 3,281 3,615g 0.0090g 400,154g
NO test 53,860 12.751 4,224 12,030h 0.0009h 13,456,577h
a Relative to the strategy with the next lower cost
b Relative to the strategy with the next lower efficacy
c Reference strategy
d Compared to the reference strategy (no trastuzumab)
e Extendedly dominated by FISH alone (extended dominance: is applied to remove from consideration strategies whose cost–effectiveness is
inferior in comparison with at least one more expensive strategy)
f Dominated by FISH alone (simple dominance: a strategy is dominated by another if the former both costs more and is less effective)
g Compared to FISH alone
h Compared to parallel IHC and FISH
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Sensitivity analysis
In deterministic sensitivity analysis, varying the price of
trastuzumab and the discount rate had substantial influence
on the results. Variation of other unit costs (apart from
trastuzumab), cancer recurrence rates, test sensitivity or
specificity, utilities or the HER-2 overexpression pattern
did not influence the ranking of strategies. The ICERs for
the non-dominated strategies were essentially sustained in
all situations analyzed (Fig. 3, Table 5). The rank order of
the testing strategies was also robust (Table 5). However, if
the specificity of FISH alone was set a low value of 0.82
(while specificity was left unchanged for the other strate-
gies), FISH confirmation of IHC2? would become the
preferred strategy due to its much higher specificity value.
None of the other analyses performed affected the prefer-
ability of FISH alone (Fig. 3).
At a willingness to pay per QALY gained of €13,333,
the FISH testing approach became dominant until at
€380,000, parallel FISH and IHC became the preferred
strategy (Fig. 4a). Further PSA results are shown in
Fig. 4b.
Discussion
We modelled the cost–effectiveness of different predic-
tive HER-2 testing strategies, prior to trastuzumab
treatment of adjuvant breast cancer patients, from a
Swiss health system perspective. FISH alone testing with
subsequent trastuzumab treatment of HER-2-positive
patients was identified as the most cost–effective
approach, with an ICER of €12,245 per QALY gained
compared to no trastuzumab use. It dominated other
testing strategies or these showed unfavourable cost–
effectiveness ratios. Sensitivity analysis showed these
results to be robust over a wide range of assumptions. As
a limitation, we did not take into account a possible
Fig. 2 Cost–effectiveness analysis. Graphical representation of
incremental cost–effectiveness results. IHC alone (2–3?) is domi-
nated by FISH alone, i.e. less effective and more expensive. IHC first
(FISH only 2?) is extendedly dominated by FISH alone, i.e. less
expensive but also less cost–effective. For the remaining strategies,
the slope of the dotted line represents incremental cost–effectiveness
Fig. 3 Plot of the deterministic sensitivity analyses for parameter
uncertainty with regard to the ICER of FISH testing compared with
no trastuzumab. Larger bars indicate stronger sensitivity of the base
case ICER of FISH testing versus the reference strategy to uncertainty
around the respective parameters. DF disease free, FISH fluorescence
in situ hybridisation, ICER incremental cost–effectiveness ratio, IHC
immunhistochemistry, LLR local/regional recurrence, LR local recur-
rence, MD metastatic disease, MR metastatic recurrence, NT no
trastuzumab, P probability, RR regional recurrence, Sens sensitivity,
Spec specificity, T trastuzumab. *In this sensitivity analysis, FISH
confirmation of IHC2? becomes the preferred strategy with an ICER
of €13,448 compared to reference strategy
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influence of false positive and false negative test results
on the event risks reported in HERA and in the other
trials used for deriving transition probabilities in this
modelling study. This would have required complex
correction procedures and tentative assessments indicated
a minor impact.
Table 5 One-way sensitivity analysis of incremental costs (€) per QALY gained (ICER) without dominated strategies
Testing strategy FISH alone vs.
no trastuzumab
Parallel testingc
vs. FISH alone
NO TEST vs.
parallel testing
Baseline 12,245 400,154 13,456,577
Price trastuzumab ?30% 15,982 531,788 17,377,558
Price trastuzumab -30% 8,507 268,544 9,549,342
Price all predictive tests ?30% 12,398 398,547 13,396,396
Price all predictive tests -30% 12,091 401,785 13,530,503
Cost of FISH test probe -50% 11,892 400,129 13,655,867
Cost metastatic basis treatment ?30%a,b 11,806 399,727 13,463,011
Cost metastatic basis treatment -30%a,b 12,683 400,605 13,463,889
Cost local recurrence ?30%a 12,181 400,102 13,463,386
Cost local recurrence -30%a 12,308 400,230 13,463,514
Cost regional recurrence ?30%a 12,243 400,164 13,463,448
Cost regional recurrence -30%a 12,246 400,168 13,463,451
Discount rate 6% 18,721 636,009 21,215,854
Discount rate 0% 7,644 230,451 7,818,473
a Without consideration of hormone therapy
b Price for trastuzumab not included
c Parallel both tests (BTP): either IHC (2–3?) or FISH? test result needed for HER-2? status
Fig. 4 Results from the
probabilistic sensitivity analysis
(PSA). a Acceptability frontier.
The cost–effectiveness
acceptability frontier shows the
PSA-based probability of
testing strategies of being cost–
effective. For different
willingness to pay thresholds,
different strategies are optimal.
For each threshold, only the
probability for the optimal
strategy is shown.
b Incremental cost (€)–
effectiveness scatter plot of all
testing options. The cost–
effectiveness scatter plot uses
the cost–effectiveness plane to
plot a test cost and effectiveness
pair for each recalculation of
the model (10,000 runs)
Breast Cancer Res Treat
123
In routine practice, many local laboratories only use IHC.
Central laboratories often use FISH to confirm IHC2?, as
was the case in the HERA study [12]. Both of these strategies
were dominated by the FISH alone strategy in our model.
The inferiority (extended domination) of FISH confirmation
of IHC2? was due to this strategy, clinical characteristics,
although it was cheaper than FISH alone.
In Switzerland, many central laboratories have started to
use primary FISH assays. However, IHC may be added in
unclear cases. The implications were difficult to assess as
no sensitivity or specificity data for FISH equivocal sam-
ples (HER-2/CEP17 ratio signal between 1.8 and 2.2) were
available from the literature. A tentative assessment
assuming a hypothetical sensitivity of 0.892 (CI 0.766–
0.94 [30, 31]) indicated a quality-adjusted survival of
12.470 QALYs and hence no further gain in clinical
effectiveness.
In a recent cost–effectiveness analysis in the metastatic
setting, conducted by Elkin et al., trastuzumab treatment
without predictive testing was dominated by a testing
strategy not covered here, namely, the confirmation of
IHC2? or 3? with FISH [26]. Only patients with a positive
result in both tests received trastuzumab, i.e. considerably
fewer than in our combined IHC and FISH strategy. It may
indeed make sense to use stricter criteria for trastuzumab
treatment in the metastatic than in the adjuvant setting.
However, the strategy of FISH confirmation of IHC 2–3?
was also assessed for non-metastatic patients. In a meta-
analysis by Dendukuri et al. [17], focusing on invasive
breast cancer patients, and in a Swedish cost–effectiveness
analysis studying adjuvant breast cancer patients [27], it
was again identified as the strategy with the best ICER. Of
note, the former study only took into account diagnostic
costs; it disregarded trastuzumab costs [17]. The latter
estimated IHC scores from FISH results, based on Elkin
et al. [26], and thus made an implicit assumption of
dependency of IHC and FISH. In a separate implementa-
tion of the model, we estimated the lifetime costs and
effects of the strategy defined by Elkin et al. in the adjuvant
setting. After reducing sensitivity (0.892, CI 0.766–0.94)
and increasing specificity (0.975, CI 0.950–0.989) [30, 31],
costs summed up to €36,706 in combination with 12.697
QALYs gained. Indeed, this would imply a favourable
ICER. However, due to a low practical relevance in the
adjuvant setting, and presumable lack of acceptability in a
resource-rich setting, we did not incorporate this strategy
into the main analysis.
Recent evidence suggests that HER-2 expression in
primary and advanced tumour tissue may be discordant by
5–10% [52–57]. HER-2 status may therefore be re-assessed
before starting trastuzumab treatment in metastatic breast
cancer patients experiencing disease progression. However,
our model focuses on adjuvant therapy and we did not
attempt to assess the economic implications of this
approach, as currently, this is not routine practice.
A recent review favours FISH over IHC for accuracy,
reproducibility and precision reasons [16]. According to
this source, 15–48% of equivocal IHC2? breast cancers
show HER-2 gene amplification. In addition, 2–8% of IHC
0/1? breast cancers are FISH amplified. Around 5–22% of
IHC 3? breast cancers have no gene amplification (false
negativity) [16]. In addition, a positive FISH status points
towards a stronger responsiveness to trastuzumab. The use
of FISH testing diminishes the number of patients eligible
for trastuzumab therapy due to both superior sensitivity and
specificity compared to IHC [16]. These findings favour
primary FISH testing and are consistent with our health
economic result.
Conclusion
Clinically useful predictive tests with reasonable sensitivity
and specificity to predict drug-response are one cornerstone
in achieving a cost–effective implementation of new
treatment strategies in oncology. Currently, many novel
predictive assays (e.g. k-ras testing in colorectal cancer,
EGFR mutation analysis in lung cancer) are being intro-
duced. Results from carefully conducted health economic
analyses should inform future guidelines on the use of such
tests. In the adjuvant breast cancer setting, primary FISH
testing with subsequent trastuzumab treatment of HER-2-
positive patients is a cost–effective and preferable
approach.
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Abstract Breast cancer is the leading cancer type diagnosed among women in
Western countries. Despite great advances in cancer therapies, many of these
patients develop non-curable metastases. The objective of cancer treatment
in the metastatic setting is mainly to control symptoms and to prolong sur-
vival. The selection of the optimal chemotherapeutic regimen is affected by
performance status, tumour biology, site and extent of the disease and the
exposure to prior therapies. Recent developments in new kinds of cancer
drugs have contributed not only to immense progress in clinical outcomes
but also to dramatically increased treatment-related health costs. Cost-
effectiveness analysis is a type of economic evaluation that compares costs
and health outcomes of alternative intervention strategies in a systema-
tic way.
REVIEWARTICLE Pharmacoeconomics 2010; 28 (8): 629-6471170-7690/10/0008-0629/$49.95/0
ª 2010 Adis Data Information BV. All rights reserved.
In this review, a systematic literature search was performed and the evi-
dence on the cost effectiveness of conventional chemotherapy and targeted
therapy for metastatic breast cancer was explored.
Cost-effectiveness/-utility analysis of treatment regimens for metastatic
breast cancer were identified using literature and reference searches (MED-
LINE). Published reports on conventional and targeted cancer therapies were
scrutinized and incremental cost-effectiveness ratios (ICERs) were ab-
stracted. Furthermore, the quality of reporting, as well as methodological and
modeling issues, were extensively discussed.
From full-text article reviews, six cost-effectiveness analyses on conven-
tional therapies and seven studies on targeted therapies were included. Eight
analyses were conducted in European countries, three in the US and two in
Canada. The economic models were primarily (69%) based on clinical trial
data. Results from sensitivity analyses and study perspectives were reported
by all studies. Discount rates were mentioned in five articles (39%). The meth-
ods of reporting costs and effects varied considerably, as did trial design across
conventional chemotherapies, which made it difficult to compare those analyses.
The pharmacoeconomic studies came to different conclusions. The actual
clinical evidence does not suggest one conventional chemotherapy regimen
as superior. Studies on cytotoxic agents showed mainly favourable cost-
effectiveness ratios. Targeted therapies indicated both favourable and non-
favourable ratios. Currently, trastuzumab is the only antibody-based
targeted therapy that is established in the clinic for the metastatic setting.
Breast cancer is the most common cancer di-
agnosed in women in Western countries. About
25–40% of breast cancer patients develop a met-
astasis in the course of their illness.[1,2] Since
metastatic breast cancer (MBC) is not curable,
one of the main goals of treating patients is to
provide palliation of symptoms and the main-
tenance or improvement of quality of life (QOL).
The prolongation of life expectancy is a second-
ary goal. The armamentarium for palliative
treatment contains potent endocrine treatments
for the hormone receptor-positive breast cancers,
bisphosphonates for the subset of patients with
bone disease, targeted therapy for, so far, mainly
the subgroup of HER2 (human epidermal growth
factor receptor 2)-positive patients and, finally,
conventional cytotoxic chemotherapy.
Conventional chemotherapeutics do not act
on the diverse signalling pathways that help the
tumour progress, but rather target dividing cells
in general and are therefore associated with a
wide range of adverse effects. For breast cancer,
in particular, conventional chemotherapy for
metastatic disease is usually administered after
the failure of endocrine treatment. A high percen-
tage of patients with early breast cancer receive
adjuvant combination chemotherapy, which af-
fects the choice of the regimen administered for
MBC. Patients with breast cancer recurring after
having received anthracyclines in the adjuvant
setting usually receive a taxane-containing regi-
men, whereas patients who have received adjuvant
taxanes usually receive an anthracycline-based
regimen.[3]
Targeted drugs exploit specific molecular
characteristics of the tumour and do not usually
affect cells without that specific target. Several
classes of antibody-based targeted therapies have
raised hope in the treatment of breast cancer.[4]
Trastuzumab (Herceptin!, Roche Pharma,
Switzerland), a monoclonal antibody targeted to
the HER2 receptor is currently routinely used in
both the early breast cancer and metastatic set-
tings for patients with HER2-positive tumours.[5]
The efficacy and safety of trastuzumab as first-
line treatment in MBC has been demonstrated in
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several randomized controlled trials.[6-9] How-
ever, trastuzumab is limited to 15–25% of breast
cancer patients overexpressing the HER2 re-
ceptor or amplifying the HER2 oncogene.[10-12]
Lapatinib is an orally available dual tyrosine ki-
nase inhibitor of the HER2 kinase and has been
approved in some countries for HER2 MBC
progressing under trastuzumab treatment or as
first-line oral treatment in combination with
endocrine therapy.[13] Pertuzumab, a further
monoclonal antibody that binds a different epi-
tope on HER2 from trastuzumab is under clinical
assessment. This agent has been developed for
breast cancer patients, whether overexpressing
HER2 or not.[14,15] Bevacizumab (Avastin!, Roche
Pharma, Switzerland) is a monoclonal antibody
directed against vascular endothelial growth
factor-A. Given its antiangiogenic properties, it
is being evaluated in the metastatic setting, and
is showing promising results.[16] Bevacizumab
has been approved in a combination therapy
for MBC with a negative HER2 status.[17]
The complex economics of new oncology drug
developments are an important area of re-
search.[18] However, progress in the development
of new cancer treatments is connected to costs,
namely treatment-related expenses and effects on
QOL. Particularly expensive drugs must demon-
strate relevant improvements in regard to length
of life, QOL or if there is no alternative available
to be regarded as justified.[19,20] In response to the
growing concern about the costs of pharmaceu-
tical products, pharmacoeconomic studies in-
vestigate the impact of new drugs or interventions
on the patient’s QOL and the healthcare outcome
through, for example, cost-effectiveness studies.
Economic analyses ideally cover clinical and
economic outcomes achieved in randomized
controlled trials. Such models play an important
role in policy makers’ decisions regarding cover-
age and reimbursement of products.
The aim of this review was to compare and
summarize findings of published, original cost-
effectiveness analyses of chemotherapy and tar-
geted non-chemotherapy regimens for MBC that
presented results as cost-per-life-year gained
(LYG) or QALY. The quality of reporting was
critically assessed. Particular emphasis was
placed on the key drivers of cost effectiveness of
the various treatment agents.
1. Literature Review
1.1 Data Source and Selection
MEDLINE and PubMed were searched sys-
tematically for all original cost-effectiveness
analyses published between 2000 and 2009. Given
that the field of targeted therapies is new, we in-
cluded studies published only from the year 2000
onwards to ensure a comparable study population
in both conventional and targeted therapeutic
settings. The search included the following key-
words: ‘cost’, ‘effectiveness’, ‘utility’, ‘breast’,
‘cancer metastatic’ and ‘advanced’. A total of 671
articles were recognized in the initial literature
search. Titles and abstracts were screened by two
independent reviewers (KJD, PRB) to determine
whether the reports were an original health eco-
nomic study. The full text of studies considered
important after the first screening cycle were
evaluated. For literature saturation, reference
lists were explored for relevant reports. Studies
were included if they were reports on cost effec-
tiveness, or cost-utility reports ofMBC therapies.
Descriptive cost studies, posters, editorials, pub-
lications not showing primary data or reports in
languages other than English were excluded.
Cost-effectiveness analyses primarily describing
the health economic impact of hormonal thera-
pies or predictive testing in targeted non-chemo-
therapy settings were not taken into account.
Figure 1 outlines how the final sample size was
reached.
Detailed information from the reports was
abstracted using a pre-specified checklist. A
standardized extraction form was used to gather
the following issues from the studies: (i) char-
acteristics of the study (study design, population,
perspective); (ii) type and outcome of the eco-
nomic analysis; and (iii) key aspects (cancer
treatment and comparator strategy, clinical out-
come, costs and discount rate) and parameters
of the sensitivity analysis (if available). For the
base-case analysis, incremental cost-effectiveness
ratios (ICERs) were reported. Studies were
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grouped into cost-effectiveness analyses addres-
sing either conventional chemotherapy or tar-
geted regimens. Particular emphasis on the key
drivers of cost effectiveness of the various chemo-
therapy and targeted regimens was given. As
year of reference, the reported monetary year or
the year of publication was used. Costs are shown
in $US (h1D $US1.47; d1D $US1.74; $Can1
D $US1).
2. Overview of Included Papers
Included studies focused on breast cancer
patients in MBC. Outcome measures were given
in either QALYs (7 of 13) or in LYG (6 of 13).
Eight analyses were conducted in European
countries (France, Greek, Norway, Switzerland,
UK), three in the US and two in Canada. Only
one article was published in a pharmacoeconomic
and outcome research journal,[21] whereas the
remaining articles were published in oncology or
public health journals. The funding source was
mentioned in nine studies (69%).
The methodologies used varied considerably.
The studies all used model-based analyses for
their calculations. Three articles[21-23] mentioned
that Markov models had been established,
whereas only two clearly described the method-
ological approach of the model. The remaining
studies used other economic models. Data in-
cluded were derived primarily from randomized
controlled trial data (9 of 13). Two studies[24,25]
were based on cancer registry and medical record
information, respectively. One study[26] was con-
ducted with data from an open, controlled, pro-
spective study and one article[27] included data
from published literature. The studies were si-
mulated from a healthcare payer (10 of 13), a
hospital (1 of 13) or a societal (2 of 13) perspec-
tive. A discount rate of 3% (3 of 13), 3.5% (1 of
13) or 5% (1 of 13) was applied. The discount
rates were largely applied to both costs and out-
comes. The remaining studies did not state dis-
count rates. In the sensitivity analyses performed,
mainly costs and clinical effect variables were
varied. The economic analyses based on con-
ventional chemotherapies were all considered
cost effective by the authors, except one study
with ixabepilone.[28] In the studies of targeted
regimens, authors concluded that the monoclonal
antibody treatment was cost effective (3 of
7),[25,26,29] not cost effective (3 of 7)[22,23,27] or
gave no clear statement (1 of 7).[30]
The summary of cost-effectiveness results of
conventional and targeted regimens is given in
tables I and II, respectively.
3. Cost Effectiveness of Conventional
Chemotherapies
Maniadakis et al.[32] analysed the cost effec-
tiveness of three taxane-based regimens that are
7 (TR)1
6 (CT)
• Final inclusion after abstract/full text
 screening
• After title screening
• Articles published
 after/within 2000
• Initial search
75
435
671
Fig. 1. Article search. 1 One article was included as a result of the reference search. CT = articles on conventional chemotherapies;
TR =articles on targeted regimens.
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administered as first-line chemotherapy in patients
with MBC who have already received anthracy-
clines in the adjuvant setting. This economic
analysis, conducted from the perspective of the
Greek national health system, was based on the
randomized phase III trial[42] comparing carbo-
platin (area under the curve [AUC] of 6) and
paclitaxel (175mg/m2 administered every 3 weeks
for six cycles) versus paclitaxel weekly (80mg/m2
weekly for 12 weeks) or docetaxel 75mg/m2 plus
gemcitabine 1000mg/m2 every 3 weeks.[43] The
paclitaxel weekly arm appeared to be the most
preferable choice among the three regimens as it
prolonged overall survival (OS) more than the
other combinations without being associated
with higher adverse effects. The QOL was similar
in all three arms. Docetaxel with gemcitabine in-
curred the lowest total costs per patient (h19 343;
$US28 434) but proved to be less effective than
the two paclitaxel-containing regimens and
caused more severe myelotoxicity and mucositis.
Paclitaxel with carboplatin every 3 weeks cost
about the same amount per patient as paclitaxel
weekly (h20 498 vs h20 578; $US30 132 vs
$US30 250) but was significantly less effective.
These results remained fairly constant in sensi-
tivity analyses.
Vu et al.[34] compared the cost effectiveness of
docetaxel 100mg/m2 versus paclitaxel 175mg/m2,
both administered every 3 weeks. The analysis
was conducted from the perspective of the
Canadian healthcare system. The clinical data, in
contrast to many other cost-effectiveness studies,
was not based on a clinical trial but was derived
from a provincial cancer registry. The OS in the
docetaxel-treated group was significantly higher
than among patients treated with paclitaxel (10.9
vs 8.3months). This benefit was similar to the results
of a randomized trial comparing both agents.[44]
The costs per patient were substantially higher in
the docetaxel group ($Can9441 vs $Can2944;
$US9441 vs $US2944), which was attributed to
the higher acquisition costs of docetaxel. The
ICER was $Can30 337 ($US30 337) per LYG for
docetaxel versus paclitaxel.
Benedict et al.[35] compared the same regimens
for the UK healthcare system as Vu et al.[34] but
used clinical data from a randomized controlled
trial.[45,46] In contrast to Vu et al.,[34] Benedict
et al.[35] included QOL data retrieved from the
literature. Furthermore, the authors indirectly
included two additional regimens (paclitaxel
weekly and nab-paclitaxel1 every 3 weeks) by in-
cluding data from other randomized controlled
trials. However, for paclitaxel weekly, evidence
from two abstracts from meeting proceedings
was used rather than the best available evi-
dence.[48] In the model, the hazard ratios of doc-
etaxel, paclitaxel weekly and nab-paclitaxel every
3 weeks were applied to the baseline hazard with
paclitaxel every 3 weeks to model the progression-
free and OS curves. The proportion of patients in
each of the three health states (no progression,
progression, death) was calculated at each time
point for each treatment.
The relative difference between the mean costs
per patient in the docetaxel 3-weekly group versus
the paclitaxel 3-weekly group was smaller than in
the population-based analysis for Canada.[34]
Furthermore, the clinical benefit derived from a
randomized clinical trial was higher than in the
Canadian study, proving that data from ran-
domized controlled trials are not always repro-
ducible in clinical practice. The ICER was found
to be d4583–14 694 ($US7974–25 567) per QALY
for docetaxel 3-weekly compared with paclitaxel
3-weekly, weekly and nab-paclitaxel, which is
regarded as acceptable for the UK healthcare
system.
Verma and Ilersich[36] compared the costs and
outcomes of oral daily capecitabine 2500mg/m2
plus 3-weekly docetaxel 75mg/m2 with 3-weekly
docetaxel 100mg/m2 from the perspective of the
Canadian healthcare system by combining data
from a randomized controlled trial[49] with a
population-based model. The randomized clin-
ical trial showed a survival benefit of 3 months
(14.5 vs 11.5 months) for the combination treat-
ment. Combination treatment was accompanied
with an increase in grade 3 adverse events (71% vs
1 Recently, a new nanoparticle albumin-bound formulation of paclitaxel (nab-paclitaxel) was developed to
improve efficacy and overcome the toxicity associated with taxanes.[47]
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49%), whereas the monotherapy arm showed a
slightly higher rate of grade 4 events (31% vs
25%). The ICER for the combination treatment
was $Can3691 ($US3691) per LYG.Unfortunately,
this analysis did not account for QOL.
The efficacy and safety of nab-paclitaxel in the
first- and second-line treatment of MBC were
demonstrated in a large randomized trial with
paclitaxel serving as the control arm. In that
study, nab-paclitaxel was statistically superior to
paclitaxel in terms of objective tumour (33% vs
19%; p = 0.001) and progression-free survival
(PFS) [23 vs 16.9 weeks; p= 0.006].[50] There was
also a trend in favour of nab-paclitaxel in OS, but
it did not reach statistical significance (median
65.0 vs 55.7 weeks; p= 0.37). Patients randomized
to the nab-paclitaxel arm had a lower incidence of
neutropenia but higher grades of sensory neuro-
pathy. In another trial, different dosages of nab-
paclitaxel were compared with the other taxane,
docetaxel. The trial compared two dosages for
weekly administration (100 and 150mg/m2) and
an every 3 week (300mg/m2) schedule of nab-
paclitaxel versus docetaxel.[50] Nab-paclitaxel
150mg/m2 weekly demonstrated significantly
longer PFS than docetaxel by both independent
radiologist assessment (12.9 vs 7.5 months, re-
spectively; p = 0.0065) and investigator assess-
ment (14.6 vs 7.8 months, respectively; p= 0.012).
Based on these data, which included only PFS
data and noOS data, Dranitsaris et al.[31] conducted
an economic evaluation from the perspective of the
UK healthcare system. Nab-paclitaxel 150mg/m2
weekly was associated with the highest cost per
patient (d27 222; $US47 366) due to the acquisi-
tion cost and costs for supportive care (growth
factors, blood transfusions, antibacterials and
antiemetics). The docetaxel arm was the less ex-
pensive treatment arm, with d12 923 ($US22 486)
mean cost per patient. The incremental 5.4 pro-
gression-free months gained by nab-paclitaxel
150mg/m2 compared with docetaxel resulted in a
ratio of d31 800 ($US55 332) per progression-free
year gained. QOLwas not considered in this cost-
effectiveness analysis. The authors concluded that
nab-paclitaxel can be considered a reasonable al-
ternative to docetaxel as first-line chemotherapy
for MBC and, if considering the favourable ad-
verse effect profile of nab-paclitaxel, the inclusion
of QOL and utility benefits would further im-
prove its economic profile.
Finally, Reed et al.[33] analysed the cost effec-
tiveness from the perspective of the US health-
care system of adding ixabepilone to capecitabine
as third-line chemotherapy after progression un-
der anthracyclines and taxanes. The results of this
study should be cautiously compared with all
previously mentioned cost-effectiveness analyses,
as the underlying patient population had experi-
enced recurrence or progression despite treat-
ments with anthracyclines and taxanes, which is
associated with poorer response to any chemo-
therapy and poorer survival expectation as such.
Clinical data were extracted from a randomized
controlled trial,[51,52] from which QOL results were
also available and incorporated. The addition of
ixabepilone prolonged OS by 32 quality-adjusted
days. The incremental costs for the combination
therapy amounted to around $US30 000, which
resulted in an ICER of $US359 000 per QALY.
The authors concluded that this ratio is higher
than for other new treatments in MBC.
4. Cost Effectiveness of Targeted
Therapies
Norum et al.[37] described a model-based cost-
effectiveness analysis of trastuzumab in MBC
patients that included data on efficacy, toler-
ability, gain in survival and drug costs from a
third-party payer perspective. Based on data
presented at breast cancer conferences[53,54] and a
MEDLINE search, they assessed LYG and asso-
ciated costs in patients treated with standard
chemotherapy (docetaxel, anthracycline plus
cyclophosphamide or paclitaxel) compared with
the addition of intravenous (IV) trastuzumab
4mg/kg (initial dose) and 2mg/kg (weekly dose).
Direct costs included drug costs, the assessment
of HER2 status, and hospitalization and outpatient
clinic costs. Costs for the chemotherapeutic
agents were assumed to be similar between treat-
ment arms so they were not incorporated in the
model. No indirect costs were included. The in-
cremental survival time with trastuzumab was
between 0.3 and 0.7 years compared with standard
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chemotherapy. Drug costs (89% of overall costs)
and the prolonged treatment in the outpatient
clinic (8% of overall costs) were the key factors
driving costs in the trastuzumab group. Depen-
ding on survival gain and discount rate applied,
incremental cost effectiveness ranged from
h69 212 to h162 417 ($US101 742 to $US238 753)
per LYG. Drug costs and survival time signif-
icantly influenced the base-case results in sensi-
tivity analyses. The authors concluded that the
costs of administering trastuzumab to patients
with MBC for the gain of 1 year of life were
considerable.
The cost-effectiveness study of trastuzumab
published by Perez-Ellis et al.[25] was based on a
retrospective analysis of medical files and asso-
ciated cost data of HER2-positive patients trea-
ted for first metastatic progression. Trastuzumab
administration was given as a single agent or in
combination with chemotherapy (taxanes). Treat-
ment with trastuzumab was limited to 1 year or
until disease progression (standard schedule IV
4mg/kg [initial dose], IV 2mg/kg [weekly dose]).
Control patients received standard treatment
(taxanes- and/or anthracycline-based chemothe-
rapy). Treatment costs were based on hospital
direct costs (inpatient hospitalization stay, drug
costs, imagery test, etc). Costs for predictive
testing of HER2 status were omitted from the
analysis. Data on QOL were not considered. In
terms of OS, the trastuzumab group showed su-
perior results (37months vs 19months in the non-
trastuzumab group; p< 0.001). The per-patient costs
in the trastuzumab group were considerably higher
than in the non-trastuzumab group (h39 607
[$US58 222] vs h12 795 [$US18 809], respectively).
The main cost drivers were the price of trastuzu-
mab (40% of the total costs in the trastuzumab
group) and the length of hospitalization (60% of
total costs in the no-trastuzumab group). Of note,
hospital room costs and the number of imagery
tests were substantially higher in the trastuzumab
group. The ICER assessed by the bootstrapping
method was considered cost effective (h27 492
[$US40 413] per LYG). Bivariate sensitivity ana-
lysis was performed under several assumptions in
regard to trastuzumab unit costs (-25%, -50%,
-75%) and hospitalization costs (–50%). The asso-
ciated ICER ranged from h8000 ($US11 760) to
h20 000 ($US29 400) per LYG.
In an open, controlled, prospective study,
Poncet et al.[38] evaluated the costs and effects for
patients receiving a combination therapy of IV
trastuzumab (3-weekly schedule of 4mg/kg [initial
dose], 2mg/kg [maintenance dose]) and pac-
litaxel (trastuzumab + paclitaxel) or control ther-
apy (any chemotherapy without trastuzumab).
According to the medical files of those patients,
all costs generated from the hospital were in-
cluded in the analysis (overall care costs, drug
costs, immunohistochemical tumour analysis,
hospital stay, etc.). Effectiveness was assessed in
terms of OS and PFS. The 1-year OS rate showed
a significant difference between comparator and
control group (0.85 vs 0.47, respectively; p= 0.007).
The difference in 1-year PFS was not statistically
significant (60% vs 42%, respectively). The mean
ICER was h15 370 ($US22 594) per LYG for
trastuzumab. Poncet et al.[38] concluded that the
strategy of adding trastuzumab to paclitaxel
therapy seems to be affordable from the per-
spective of the French healthcare system. To ob-
tain equivalent mean cost effectiveness in both
groups, the threshold analysis evaluated that the
costs of a trastuzumab flask would need to be
h432 ($US635) instead of the h626 ($US920) paid
in 2002.
Hornberger et al.[29] assessed the cost effective-
ness of first-line trastuzumab treatment of MBC
HER2-positive patients (trastuzumab+ paclitaxel
vs paclitaxel). Trastuzumab was administed once
weekly (4mg/kg loading dose, 2mg/kg mainten-
ance dose).[55] Patients with progressing cancer
were allowed to receive trastuzumab as second-
line treatment (75% in paclitaxel group, 47% in
trastuzumab + paclitaxel group). Data on res-
ponse duration and OS were derived from a ran-
domized controlled study (n = 469).[7] The model
comprised the costs of chemotherapy; the rate,
severity and costs of adverse events; and QOL.
Clinical benefits were measured in achieved pro-
longed survival and improved quality-adjusted
life-months (QALMs). The combined therapy
arm achieved a survival mean of 25.0 months
compared with 15.2 months in the paclitaxel arm.
In addition to this, the trastuzumab +paclitaxel
Cost Effectiveness of Metastatic Breast Cancer Therapies 639
ª 2010 Adis Data Information BV. All rights reserved. Pharmacoeconomics 2010; 28 (8)
treatment gained higher QALMs than the control
group (12.3 vs 6.4 QALM, respectively), but also
increased healthcare costs by d18330 ($US31894).
However, the corresponding ICER was assumed
to be cost effective (d37 500 [$US65 250] per
QALY) and upon the recommendation of the
UK National Institute for Health and Clinical
Excellence (NICE) Appraisal Committee, treat-
ment of MBC with trastuzumab+ paclitaxel was
regarded as justified.
The majority of pharmacoeconomic studies
include only one specific indication. Garrison
and Veenstra[39] established a dynamic life-cycle
model to evaluate the use of trastuzumab in
multiple indications (adjuvant and MBC with a
HER2-positive expression pattern) to estimate
the overall economic value of the agent. Based on
publicly available data, QALYs and direct treat-
ment costs were estimated for the product life-
cycle of trastuzumab over 18 years. The authors
aimed to forecast the volume of use of trastuzu-
mab (given with paclitaxel) over the product life-
cycle as well as estimating its cost effectiveness (vs
paclitaxel alone) across early-stage and MBC
patients from a payer perspective in the US. The
model included costs for HER2 testing (im-
munohistochemistry [IHC] or fluorescence in situ
hybridization [FISH]), trastuzumab therapy until
disease progression, and supervising and treating
adverse events. The cost assumptions of trastu-
zumab treatment in MBC patients were based on
current medication costs, survival estimates and
utility weights derived from published studies.
The authors projected the number of patients
treated with trastuzumab as three times lower in
MBC than in the adjuvant setting. Accordingly,
161 000 women with MBC would be treated
during the entire modelling period. The volume
of trastuzumab use and associated costs resulted
in an indication-specific ICER of $US85 676 per
QALY gained for MBC. The ICER for the overall
life-cycle summed to $US35590 per QALY (ICER
for early breast cancer $US26417 per QALY).
One article examined the health economic out-
come of lapatinib in HER2-overexpressing MBC
patients.[41] The life-long Markov model com-
prised information on clinical effectiveness from
results of two randomized controlled trials of
lapatinib (EGF100151,[56] EGF20002[57]). Pub-
lished literature was used to gather information
on health-state utilities, direct and indirect costs
of the therapy, primary adverse events, labora-
tory tests and costs of disease progression. The
model took the US societal perspective. Adding
lapatinib to capecitabine therapy yielded addi-
tional costs of $US19 630 and 0.12 QALYs. The
corresponding ICER resulted in $US166 113 per
QALY gained. The sensitivity analyses revealed a
lower probability of 2% to reach an ICER below
$US150 000 per QALY. Hence, the willingness-
to-pay (WTP) threshold is most probably not
reachable.
The only cost-effectiveness study on bev-
acizumab in the first-line treatment of MBC was
published by Dedes et al.[40] The study group
analysed the economic outcomes of bevacizumab
plus paclitaxel versus paclitaxel monotherapy in
HER2-negative MBC patients. Study design and
data on PFS and OS were based on a randomized
clinical trial.[16] With the help of a Markov
model, cost effectiveness (expressed as costs per
QALY) was assessed. Cost data covered direct
costs of chemotherapy treatment, most im-
portant adverse events, laboratory tests and dis-
ease progression. No indirect costs were taken
into account. Utilities were derived from published
literature. The combined therapy of paclitaxel +
bevacizumab summed to additional per-patient
costs of h40 369 in combination with a gain of
0.21 QALYs. Consequentially, the ICER sum-
med to h189 427 ($US278 458) per QALY. The
subgroup analysis showed an increasing ICER
with age. Due to an improved benefit in efficacy,
the ICER of the younger population (aged 27–49
years, ICER h152 823 [$US224 650] per QALY)
was considerably lower than that of the older
population (aged 65–85 years, ICER h1 226 615
[$US1 803 124] per QALY). The impact of sta-
tistical uncertainties around the main input vari-
ables were assessed by one-way and probabilistic
sensitivity analyses. By varying time to progres-
sion (–50%) in the paclitaxel+ bevacizumab group,
this treatment strategy became dominated. The
variation of time (–50%) from progression to death
(paclitaxel arm) showed a further considerable
influence in sensitivity analysis. In conclusion,
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the authors believe that MBC treatment with
bevacizumab plus paclitaxel is high and above the
generally accepted cost-effectiveness threshold of
h60 000 ($US88 200) per QALY gained.
5. Quality Assessment of Key Modelling
Issues
Several factors may have an influence on the
cost-effectiveness ratio, including funding source,
input parameters, under-reporting and the qual-
ity of the data integrated in the model.
5.1 Input Parameters
It is of paramount importance to include reliable
input parameters in a model. Some articles[25,27,31]
mentioned in their study limitations the problem of
including data from a small trial sample size. A few
articles[21,27] were based on data from abstracts,
which is probably not the best source of reliable
information. Several trials[21,22,28,58] were powered
to show significant results in regard to clinical res-
ponse or PFS, but not in terms of OS. Hence, those
trials may identify significant improvements in pri-
mary endpoints, but the gains in survival remain
non-significant. Conducting cost-effectiveness ana-
lyses based on such results are justified, so long as
probabilistic sensitivity analyses are performed to
assess the impact of model assumptions not prin-
cipally related to statistical uncertainties.
5.2 Sensitivity Analyses
Sensitivity analyses are usually carried out in
order to estimate the influence of the statistical
uncertainties around the model inputs. All ana-
lyses included in this review performed sensitivity
analyses, but there were major differences in their
quality. Most studies conducted deterministic
sensitivity analyses to assess the robustness of the
base case by varying variables with a direct im-
pact on incremental cost within a certain range
(e.g. –30%). Clearly described probabilistic sen-
sitivity analyses were found in three articles.[21-23]
One article[25] used the bootstrapping concept,
which differs from probabilistic sensitivity ana-
lyses by drawing observations from a data set
rather than taking random points in a distribu-
tion. However, several studies[26,29,58] did not
mention how the sensitivity analyses were per-
formed or what parameters had been used. The
robustness of the study results can only be shown
if sensitivity analyses have taken all variables into
account, especially those with a potential impact
on the cost-effectiveness ratio. Critical compon-
ents in a sensitivity analysis are prices and quan-
tities, functional relationships, the health-related
QOL measure and discount rates.
5.3 Perspective of the Analysis
Most studies took the health system perspec-
tive (77%). These analyses do not take into ac-
count indirect costs, although improved cancer
survival enhances the overall social surplus (im-
proved labour force potential). However, a huge
percentage of breast cancer patients are of
working age. Given this, indirect cost savings and
gains in productivity could potentially be con-
siderable and should not be disregarded. Only
two articles[22,59] took the societal perspective, in
which not only direct and non-direct medical
costs but also indirect costs were included.
5.4 Influences on the Cost-Effectiveness Ratio
As shown in this review, the cost effectiveness
of trastuzumab was mainly influenced by the
drug cost of trastuzumab, outpatient costs and
administration costs. The expenditures for ad-
ministration can be influenced by switching from
a weekly administration interval to a 3-weekly
schedule. However, the cost-effectiveness ratio
identified by Norum et al.[37] did not significantly
improve with the 3-weekly interval when com-
pared with the weekly interval. From the
patient’s point of view, a 3-weekly schedule may
yield an enhancement in QOL. However, the
weekly administration of trastuzumab has been
shown to be superior compared with the 3-weekly
course in terms of median PFS (13.4 months vs
8.8 months, respectively).[60] Among conven-
tional chemotherapies, only nab-paclitaxel was
studied for different administration schedules.
Weekly administration of nab-paclitaxel was
associated with more total costs per patient than
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3-weekly administration but the improved clinical
benefit for the weekly schedule offset these costs.[31]
The acquisition cost was found to be a further
influential variable.[37,38] In one analysis, low-
ering the cost of a trastuzumab flask by about
h200 ($US294) meant the mean costs per LYG
would equal that achieved with conventional
chemotherapy.[38] The standard unit of trastuzu-
mab is a 150mg vial. It could be argued that
providing different sized vials (10mg, 50mg)
could lower the costs by administering only the
exact drug dosage needed.
In addition, the duration of treatment with
trastuzumab seems to be a point of discussion.
The duration scheme of the targeted therapy in
the included studies ranged between 24 weeks
(eight cycles)[38] and 1 year[25] or until disease
progression.[25,38,39] Prolonging treatment would
be associated with increased per-patient costs.[61]
5.5 Comparability of Different Studies
Typically, thresholds for cost-effectiveness ra-
tios for a novel healthcare intervention range
from $US50 000 per QALY in the US to d30 000
($US52 200) per QALY in UK.[62] Although
these thresholds are generally regarded as accep-
table, the true societal WTP for a new interven-
tion is unknown. It might be reasonable to amend
this threshold across higher- and lower-income
countries.[63] The included analyses have been
conducted in the US/Canada (38%) or Europe
(62%). The limitation of comparing studies from
various countries lies not only in striking differ-
ences in the cost and resources included. There
are different approaches and factors that have to
be considered when using model-based cost-
effectiveness analyses across different geographic
regions.[64] For the adjuvant treatment with
trastuzumab, Essers et al.[65] presented a possibi-
lity of transferring a model-based economic study
by assessing criteria and limitations of transfer-
ability. However, the main challenge to transfer-
ring and comparing results from different studies
is mainly the transparency of the methods. Given
that several studies[29,32,34,36] did not clearly
mention how the economic model was performed
(states, cycle length, software used), it is very
difficult to compare the model results. Hence, one
major problem in evaluating the quality of cost-
effectiveness analyses is under-reporting.
5.6 Role of Funding
Several analyses were conducted using funding
from pharmaceutical companies that market the
analysed drugs.[29,33,35,39,66] Some others did not
declare conflicts of interest or funding and had no
author affiliated with a pharmaceutical com-
pany.[25,32,34,37,38,40,41] Although pharmaceutical
company sponsorship has not been found to bias
individual health economic studies, it has been
reported that it is associated with reduced like-
lihood of reporting unfavourable results.[67] This
suggests that pharmaceutical-sponsored studies
are less likely to publish negative results. In fact,
among the economic analyses reviewed in this
article that reported negative or borderline results
regarding cost-effectiveness ratios, all but one[28]
were conducted and published by independent
research groups.[37,40,41]
6. Discussion
In recent years, many studies addressing the issue
of cost and effectiveness of various new regimens
for MBC have been published. Developments in
the understanding of the molecular pathology of
breast cancer have enabled the use of targeted
therapies for adjuvant andMBC. At the forefront
of development among conventional chemothera-
pies, potentially more potent drugs (docetaxel,
ixabepilone) or established drugs with improved
drug delivery formulations (nab-paclitaxel) have
entered clinical trials and are successfully used in
daily clinical practice. Therapies to target specific
cellular pathways expand effective cancer drugs
by allowing systematic patient selection. However,
the introduction of new drugs for cancer therapy
usually increases treatment costs. Pharmacoecon-
omic analyses are in great demand in order to
obtain a better understanding of the cost-benefit
ratio of promising cancer drugs.
Among the new conventional chemotherapy
regimens, there are some striking differences in
trial design and included patient populations that
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makes comparisons across the different cost-
effectiveness studies difficult. The role of anthra-
cyclines for the adjuvant and metastatic (if not
received adjuvantly) treatment of most of the
breast cancer types is still not refutable. This is one
of the main reasons that most cost-effectiveness
analyses focus on second-line therapy after either
metastatic or adjuvant anthracycline-containing
regimens. At progression or recurrence after an-
thracyclines, a taxane-containing regimen offers
the best response rates and is considered the
standard of care.[3] Despite several phase III stu-
dies conducted so far, there is still no agreement
on the best taxane-containing regimen for
second-line chemotherapy. Docetaxel has been
shown to be superior to 3-weekly paclitaxel,[44]
but a separate trial suggested that weekly pacli-
taxel is more effective than 3-weekly paclitaxel.[48]
On the other hand, docetaxel every week is in-
ferior to 3-weekly docetaxel.[68] Furthermore,
nab-paclitaxel has been compared with docetaxel
in a phase II trial and showed superiority.[50]
While phase II trials are not perfect venues to
compare agents, docetaxel was outperformed
with regard to overall response rate by nab-
paclitaxel in this setting. Similarly, the head-to-
head comparison of nab-paclitaxel with standard
paclitaxel was a comparison employing 3-weekly
paclitaxel and not the more effective weekly re-
gimen.[69] At present, it seems reasonable to
consider all three agents useful for MBC, but it is
difficult to declare a ‘best’ agent on objective
grounds. Therefore, cost-effectiveness studies
should not omit one of the above three regimens.
Unfortunately, weekly paclitaxel has been included
as a comparator in only two cost-effectiveness
studies,[21,58] and results from one study sug-
gested it was not only the most efficient regimen
but also the most cost effective.[32]
If economic studies are conducted with poor
clinical trial data, poor outcomes will result.
There is an ongoing debate over whether cost-
effectiveness analyses should only be conducted if
the difference in clinical effectiveness between
two treatment strategies is statistically signif-
icant.[70-72] However, if such data are used in
economic studies, adequate sensitivity analyses
have to be carried out to evaluate if those input
parameters have an influence on the base-case
result. Recently, Chan et al.[73] published a review
on cost-effectiveness analyses of trastuzumab in
the adjuvant setting. The authors concluded that
trastuzumab seems to be cost effective in this
setting; nevertheless, they suggested further high-
quality economic studies with clinical data
showing the efficacy of trastuzumab in clinical
practice were necessary.
Adjuvant treatment with targeted therapies
may reduce the future incidence of MBC. In our
review, we did not include any articles that as-
sessed the impact of adjuvant trastuzumab
treatment on the reduced drug usage in the future
metastatic indication in those patients.[74] From a
health economic point of view, the adjuvant and
metastatic setting should be evaluated separately,
since these are two separate decisions. If lifetime
incidence projections make a distinction between
newly and previously diagnosed MBC, bias may
occur due to epidemiological double counting,
which leads to the overestimation of costs and
effects of the cancer therapy.[39] On the other
hand, most cost-effectiveness studies are based
on clinical data of patients naive to the evaluated
targeted drug; however, developments in clinical
practice are also shifting the usage of targeted
therapies to adjuvant therapy. For example, in
the case of trastuzumab, the patient popula-
tion on which Norum et al.[37] based their cost-
effectiveness analysis are now virtually non-existent
since literally all of them receive trastuzumab in
the adjuvant setting. If these patients develop
metastases, it is not clear to what extent they will
benefit from the same targeted treatment nor
which targeted treatment is the most appropriate.
Since many new targeted treatments are gaining
market approval for various indications in breast
cancer and some are also starting to be adminis-
tered adjuvantly (such as trastuzumab and prob-
ably soon lapatinib), cost-effectiveness studies for
MBC, according to our review, often do not keep
pace with new clinical developments.
Generally, the ICER of targeted non-chemo-
therapeutics is higher than that of conventional
chemotherapeutics. Given different comparators
and treatment regimens, the lifetime ICER for
trastuzumab varied considerably. The economic
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models showed some major differences in their
approach to assessing the cost effectiveness of
targeted therapies. The economic model used was
clearly described in only a few articles.[22,23] The two
publications[22,23] focusing on bevacizumab and la-
patinib, respectively, showed no favourable ICER.
Those two studies were based on clinical trial re-
sults and clearly described the model methodology,
the parameters included and the analyses per-
formed. Furthermore, the authors did not receive
any funding from the pharmaceutical industry.
Cost-effectiveness thresholds vary between count-
ries. Usually, threshold values of $US20 000,
$US50 000 or $US100 000 per QALY or LYG are
applied.[75] In the metastatic setting, several studies
on antibody-based targeted therapies indicated an
unfavourable ICER.[37,40,41] In spite of this, trastu-
zumab has been established in clinical practice in
both the adjuvant and metastatic setting.
There are some limitations to this systematic
review. The review excluded articles written in
languages other than English. Furthermore, results
presented at meetings (abstracts) were not in-
cluded. In addition, the search was limited to the
database and the keywords described, which may
have omitted some cost-effectiveness analyses.
Cost-effectiveness analyses on new therapies
for MBC are rarely found in the published lit-
erature and high-quality economic models are
needed. For agents such as bevacizumab or nab-
paclitaxel, the clinical benefit in terms of OS is
still under investigation and it remains to be seen
if these new therapies will be established in clin-
ical practice as routine therapies.
7. Conclusions
We conducted a systematic review of cost-
effectiveness studies of chemotherapy and tar-
geted regimens for MBC. In this setting, only a
few studies were found with varying conclusions.
Studies on cytotoxic agents showed mostly fav-
ourable cost-effectiveness ratios, while those on
targeted therapies showed both favourable and
non-favourable ratios. The cost-effectiveness ra-
tio seems to be dependent on the drug price, the
extent of improvement in survival rates, and the
administration schedule. However, the inter-
pretation of cost-effectiveness studies should not
only be limited to the value of the ICER achieved.
The quality of the data and the key modelling
parameters included in the analysis should be
considered. However, in the case of trastuzumab,
the patient population included in the cost-
effectiveness analyses no longer reflects HER2-
positive MBC patients, as almost all current
patients will have already received trastuzumab
adjuvantly. Many healthcare systems will have
problems with accepting the high cost-effectiveness
ratios of some expensive cancer treatments.
Trastuzumab, for example, is widely justified due
to its clinical benefit. Pharmacoeconomic deci-
sions about the management of new agents such
as bevacizumab or nab-paclitaxel will appear as
soon as enough clinical evidence is available.
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ABSTRACT 
Purpose – monoclonal antibodies against the epidermal 
growth factor receptor (EGFR), such as cetuximab, have 
led to significant clinical benefits for metastatic colorectal 
cancer (mCRC) patients but have also increased treatment 
costs considerably. Recent evidence associates KRAS 
and BRAF mutations with resistance to EGFR antibodies. 
We assessed the cost-effectiveness of predictive testing 
for KRAS and BRAF mutations, prior to cetuximab 
treatment of chemorefractory mCRC patients.  
Experimental Design – a life-long Markov simulation 
model was used to estimate direct medical costs (€) and 
clinical effectiveness (quality adjusted life years, QALYs) of 
the following strategies: KRAS testing, KRAS testing with 
subsequent BRAF testing of KRAS-wildtypes 
(KRAS/BRAF), cetuximab treatment without testing. 
Comparison was against no cetuximab treatment 
(reference strategy). In the testing strategies, cetuximab 
treatment was initiated if no mutations were detected. Best 
supportive care was given to all patients. Survival 
times/utilities were derived from published randomised  
 
 
clinical trials. Costs were assessed from the perspective of 
the Swiss health system. 
Results – Average remaining life-time costs ranged from 
€3’983 (no cetuximab) to €24’771 (no testing). Cetuximab 
treatment guided by KRAS/BRAF achieved gains of 0.252 
QALYs compared to the reference strategy. The KRAS 
testing strategy achieved an additional gain of 0.001 
QALYs compared to KRAS/BRAF. KRAS/BRAF testing 
was the most cost-effective approach when compared to 
the reference strategy (incremental cost-effectiveness 
ratio: €67’779/QALY).  
Conclusion – new predictive tests for KRAS and BRAF-
status are currently being introduced in pathology. Despite 
substantial costs of predictive testing, it is economically 
favourable to identify patients with KRAS and BRAF 
wildtype status.  
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INTRODUCTION 
Despite substantial progress in surgery and chemotherapy 
treatments, patients with metastatic colorectal cancer 
(mCRC) generally have a poor prognosis. Monoclonal 
antibody therapy targeted against the epidermal growth 
factor receptor (EGFR), e.g. cetuximab (Erbitux®, Merck 
KGaA, Germany) has led to significant clinical benefits in 
mCRC patients1. Overexpression and activation of EGFR 
and transduction of activation signal play an important role 
in tumor progression2, 3. Recent evidence suggests that 
genetic alteration of downstream regulator proteins like 
KRAS and BRAF are associated with lack of response to 
antibody therapy4-10. Prevalence of the KRAS proto-
oncogen in mCRC is 30-45%6, 11-14, whereas about 10% of 
wild-type KRAS tumours show BRAF-V600E (BRAF) 
mutation13, 15. Mutations in KRAS and BRAF occur in a 
mutual exclusive manner in CRC cells16.  
KRAS and BRAF gene status can be assessed by 
formalin-fixed, paraffin-embedded tissue. Several methods 
are available to detect oncogenetic mutations of KRAS and 
BRAF like, e.g., direct dideoxy-sequence analysis 
(sequencing method), pyrosequencing or allele-specific 
real-time PCR or others17-21. However, the cycle sequence 
method is the “gold standard” for KRAS analysis22. In 
Swiss laboratories, DNA sequencing after Sanger (dye 
terminator cycle sequencing) is generally used23. Given 
high sensitivity and perfect specificity of these assays, 
false negative or false positive results are scarce, but 
cannot be ruled out entirely.  
Recently, the American Society of Clinical Oncology 
issued a provisional clinical opinion on testing for KRAS 
mutation in mCRC patients, stating that KRAS mutation 
should be assessed in patients with mCRC who are 
candidates for EGFR antibody therapy24. In case of a 
KRAS mutation, antibody treatment should not be 
administered24. However, international guidelines for 
performing and assessing KRAS mutations are still being 
developed25. Testing for BRAF mutation has just started in 
some laboratories. Recent clinical evidence supports 
BRAF mutation analysis, although the available testing 
procedures are fairly expensive.  
Predictive testing helps selecting the treatments patients 
will most benefit from. Additional costs of novel predictive 
tests like KRAS and BRAF have to be balanced against 
cost savings associated with avoiding treatment of patients 
who will predictably not respond to antibody treatment. 
Markov models have already been used in the metastatic 
breast cancer setting to measure the cost-effectiveness of 
different testing strategies26, 27. However, the economic 
consequences of testing for KRAS and/or BRAF mutations 
in mCRC patients have not yet been studied. The objective 
of this analysis is to assess the cost-effectiveness of 
testing for KRAS/BRAF mutations, prior to cetuximab 
treatment of chemorefractory mCRC patients, from a 
Swiss health care system perspective.  
 
METHODS 
Overview of mCRC disease model 
Based on a previously used modelling framework28, we 
constructed a Markov state-transition model with an one-
months cycle length to assess the economic 
consequences associated with each testing strategy. 
Effectiveness was assessed in terms of quality-adjusted 
life-years (QALYs). On this basis, incremental cost-
effectiveness ratios (ICERs) were calculated. The time 
horizon of the analysis was life-long.  
Costs were assessed from the perspective of the Swiss 
health care system. Accordingly, non-medical direct costs 
and indirect costs were not taken into account. Direct 
medical costs included drug costs, costs for predictive 
testing (where applicable), diagnostic procedures and 
hospitalization. Costs and effects were discounted at an 
annual rate of 3%29. Costs are expressed in Euros (€). An 
exchange rate of €1.00 = CHF1.50 was used (February 
2010).  
The Markov model was implemented in TreeAge Pro® 
2009 (TreeAge Software Inc, Williamstown, MA, USA).  
 
Patient population studied 
The model followed a hypothetical cohort of 
chemorefractory, mCRC patients aged 50 years (45% 
female, 55% male)30. It was assumed that 70% of patients 
were wild-type KRAS and that 8% of this group (6% of the 
total) had a BRAF mutation status8, 16, 31, 32. The eligibility 
criteria of our patient population were defined by the phase 
III National Cancer Institute of Canada Trial Group CO.17 
(CO.17) study33. In brief, patients had advanced colorectal 
cancer (Eastern Cooperative Oncology Group 
performance status 0-2) with immunohistochemically 
detectable EGFR expression. They were chemorefractory 
and no other anticancer therapy was available33. 
The influence of all-cause mortality on the survival 
experience of the cohort was modeled using Swiss life 
tables34. 
 
Strategies compared 
Following testing strategies were assessed: KRAS alone 
and a sequential approach with BRAF testing of all KRAS 
wild-type patients. Patients with KRAS wild-type (in the 
KRAS alone strategy), or with KRAS wild-type/BRAF wild-
type status, received cetuximab. Best supportive care 
(BSC) was administered to patients with KRAS mutation or 
BRAF mutation. Costs and effects of the no cetuximab 
treatment strategy served as reference values. 
Administering cetuximab to the entire patient population 
without prior predictive testing (no testing strategy) was 
added to estimate the overall benefit of predictive testing. 
The occurrence of false positive and false negative test 
results may have severe consequences for the affected 
patients. Information on sensitivity and specificity of 
mutation analyses (sequencing method) were derived from 
published literature22. The probabilities of false positive 
false negative test results were assumed to be the same 
for KRAS and BRAF, each taken by itself. Sensitivity and 
specificity of the KRAS and BRAF testing strategy were 
evaluated according to the “believe-the-positive” approach, 
i.e. the combined result was positive if one test indicated a 
positive result (mutation). Both tests were regarded as 
conditionally independent (Table 1)35. 
 
Disease stages and clinical data sources 
The Markov model was build up with three commonly 
exhaustive and mutually exclusive health states: 
stable/responsive disease, disease progression and death. 
All patients entered the model in the stable state and they 
could remain stable or progress. Patients with progressive 
disease could remain in this state or die (Figure 1). 
Transition probabilities were assessed from median time to 
progression and median time to death, as observed in the 
phase III randomized CO.17 trial32, 33. The treatment effect, 
namely transition probabilities for patients with KRAS wild-
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type and KRAS mutation, was modeled dependent on 
mutation status and treatment given4-6, 9, 32. Monthly 
survival rates and median time to disease progression 
were taken from the CO.17 trial, which compared BSC 
plus cetuximab with BSC33. Data for transition probabilities 
of patients with a BRAF mutation status under cetuximab 
treatment were extracted from retrospective analyses of 
mCRC patients treated with cetuximab in different centres8, 
9. We assumed that patients with BRAF mutation receiving 
BSC would have the same transition probabilities as 
patients with a KRAS mutation in the CO.17 BSC arm 
(Table 2).  
Utilities 
Preference-based measures of health-related quality of life 
were available from the CO.17 study. They were 
prospectively collected using the self-reported Health 
Utility Index Mark 3 (HUI3) questionnaire36, 37. Mean utility 
in the wild-type cetuximab group (stable disease state, 
responding to treatment) was 0.72 (CI 0.49-0.95) at 
baseline and increased over time (0.77; CI 0.55-0.99 at 
week 24). Mean utility in the BSC group was 0.71 (CI 0.47-
0.95) at baseline and decreased over time (0.70 at week 
24; CI 0.56-0.94)37. In our model, the latter values were 
applied to both wild-type and mutant patients in the stable 
disease state without cetuximab treatment and to mutant 
patients with cetuximab. For patients in a progressed state, 
a value of 0.5 (0.45-0.72) was assumed38-40.  
 
Medical resource use  
Best supportive care 
BSC was given to all patients. Given that patients were 
assumed to be chemorefractory, BSC therapy consisted 
mainly of palliation of symptoms and improvement of 
quality of life33, 41. Concomitant therapy (antibiotics, 
opiates, steroids, antithrombotics, antidiarrheals, 
antiemetics, blood formation products) and episodes of 
hospitalization were assumed to be the same for all 
patients, during a given period of time (e.g. month of 
follow-up)37. Quantities of medical interventions such as 
diagnostic and therapeutic interventions were assessed on 
the basis of published literature37. Length of average 
hospital stay for colorectal patients was based on data 
provided by the Swiss Federal Statistical Office 
(Appendix.1).  
The model considered differences in medical resource use 
between the treatment groups (reference and cetuximab 
group) which arose from different survival times. 
 
Reference group  
All patients in the reference strategy (no cetuximab) 
received BSC only (as described above). Concomitant 
therapy, diagnostic ultrasound and palliative surgery 
including hospitalization were used in these patients. For 
the evaluation of disease status, all patients had a monthly 
medical consultation, chest radiologic imaging and cross-
sectional imaging every eight weeks, and a magnetic 
resonance imaging (MRI) at baseline (Appendix.1)33.  
 
Cetuximab group 
Patients with wild-type KRAS/BRAF status received BSC 
(as described above) plus cetuximab; in the no testing 
strategy all patients received BSC plus cetuximab. 
Cetuximab was given until disease progression or 
intolerable toxicity. For tumor evaluation, diagnostic tests 
were used as described above (Appendix.1)33. The 
cetuximab treatment group was assumed to have 
physician outpatient assessments every week due to the 
infusion schedule of the drug. The dosing regimen of 
cetuximab matched the treatment schedule described 
elsewhere32, 33. An intravenous loading dose of 400mg/m2 
body surface area was followed by a weekly maintenance 
dose of 250mg/m2. Adjusting for the gender distribution in 
Swiss incident cases30, the model assumed a loading dose 
and a maintenance dose of 706mg and 441mg, 
respectively. Administration costs for drug infusion were 
taken into account.   
Unit costs 
Costs for laboratory tests, diagnostic interventions and 
drug administration time were estimated based on 
resource utilization, and were multiplied by unit costs 
drawn from the official Swiss tariff list (Tarmed)42. Drug 
costs were based on official Swiss pharmacy prices 
(Appendix.1)43. Average hospital length of stay was 
obtained from Swiss hospital statistics44, 45. According to 
the Swiss Federal Office for Statistics, 50% of hospital per 
diem costs were paid by Statutory Health Insurance, the 
rest is covered by cantonal authorities45, 46. Hence, the 
hospitalization costs were computed on this basis (case-
based lump sum €1'127 plus daily rate of €152)44. 
Concomitant therapy was assumed to be the same for all 
patients, hence those costs were not included37.   
Sensitivity analysis 
Deterministic sensitivity analysis 
One-way sensitivity analyses assessed the robustness of 
the base-case results. Parameters subject to statistical 
uncertainty (utility values, sensitivity and specificity of 
mutation analyses) were varied within their 95% 
confidence intervals (CIs)47. The prevalence of KRAS and 
BRAF mutations was varied between 0.25-0.4017, 48 and 
0.05-0.2215, 49, respectively.  
Variables not subject to statistical uncertainty were 
considered in scenario-analyses. Variables with direct 
impact on the ICER were varied by ±30%: costs of 
cetuximab, of mutation analyses, and of palliative care of 
metastatic disease. Medical resource use (diagnostic 
interventions) was varied in the BSC group only. Discount 
rates of 0% and 6% were additionally assessed  
 
Probabilistic sensitivity analysis 
Probabilistic sensitivity analysis (PSA; second order Monte 
Carlo simulation) estimated overall parameter uncertainty 
around the base-case by using 10,000 sets of parameter 
values, which were randomly sampled from statistical 
distributions reflecting the ranges of variation used in 
deterministic sensitivity analysis44. Beta-distributions were 
used for KRAS mutation/BRAF mutation prevalence, and 
test sensitivity and specificity. Triangular distributions were 
used for utility during stable disease and after progression. 
Gamma-distributions were used for median survival times 
and median time to progression. Unit costs were not 
subject to uncertainty and not included in the PSA42.  
 
RESULTS 
Base-case analysis 
Cost 
In the base-case analysis, the addition of cetuximab to 
BSC increased costs considerably. As cetuximab use was 
restricted to patients who benefited most from therapy, the 
increase in costs in the testing strategies was distinctly 
lower than in the no-testing strategy. The costs of mutation 
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analysis (€394 per analysis) were overcompensated by 
savings associated with the restriction of cetuximab 
administration to expected responders. Average lifetime 
per-patient costs were €21’092, €21’641 and €24’771 in 
the KRAS/BRAF, KRAS and no testing strategies, 
respectively. If KRAS/ BRAF testing was used, per-patient 
savings would be €549 and €3'679 compared to KRAS 
testing and the no-testing strategy (Table 3).  
 
Effect 
Given imperfect sensitivity and specificity of the mutation 
analyses, different testing strategies led to different clinical 
outcomes (Table 1). Some patients had false negative or 
false positive results and hence, received cetuximab or 
BSC treatment inappropriately, translating into QALY loss. 
Accordingly, the no testing strategy led to the highest 
QALY result (0.700 QALYs/patient). The KRAS/BRAF and 
KRAS testing strategies accrued 0.696 and 0.697 QALYs, 
respectively. The lowest result was observed in the 
reference strategy with no cetuximab use (0.443 QALYs) 
(Table 3).  
 
Incremental cost-effectiveness 
The least costly and least effective approach was the 
reference strategy (no cetuximab) (Table 3). Testing for 
KRAS and BRAF mutations led to average per-patient 
costs of €17’109 and a quality-adjusted survival time of 
0.252 QALYs, translating into an ICER of €67’779/QALY 
gained, compared to no cetuximab. Testing for KRAS only 
led to an ICER of €466’725/QALY versus KRAS and BRAF 
testing. The regimen with no predictive testing showed an 
even less favourable ICER (€1’076’591/QALY versus 
KRAS) (Figure 2).  
In Switzerland, about 4011 new colorectal cancer patients 
are registered annually (average 2003-2006)30. If 25% 
(1’003) of these patients developed metastatic disease50, 
51, KRAS and BRAF testing would lead to annual direct 
cost savings of €550’666 and a loss of 1.18 QALYs 
compared to KRAS. In comparison with no testing, KRAS 
and BRAF testing would save €3’690’042 and imply a loss 
of 4.10 QALYs, per year. Compared to the no cetuximab 
strategy, the usage of KRAS and BRAF mutation analysis, 
with subsequent cetuximab administration where indicated, 
would require an annual net investment of about €17.2 
million to acquire a gain of 253 QALYs. 
 
Sensitivity analysis 
The results of the deterministic sensitivity analyses 
indicated that varying the utility value for progressive 
disease had the strongest impact on the ICER (Appendix 
2). The rank order of strategies was sustained in all 
situations assessed. The impact of the scenario analyses 
on ICER results was minor (Appendix.3). 
In PSA, KRAS and BRAF testing was the dominant 
strategy over a willingness to pay range of €10’000-
€80’000 per QALY gained. Beyond €80’000/QALY, KRAS 
became the preferred strategy (Figure 3). Further PSA 
results are presented in Appendix.4.  
 
DISCUSSION AND CONCLUSION 
This present work is the first study addressing the cost-
effectiveness of predictive KRAS and BRAF testing, prior 
to cetuximab administration to mCRC patients. Testing for 
KRAS and BRAF status with subsequent cetuximab 
treatment of patients with confirmed wild-type showed the 
most favourable ICER, of €67’779/QALY gained compared 
to no cetuximab use. Robustness of results was 
ascertained in a wide range of sensitivity analyses.  
According to the revised prescribing information, mCRC 
patients with KRAS mutations are not recommended to 
receive cetuximab, as they are unlikely to benefit from anti-
EGFR drugs52. Given this, KRAS assessment is routine 
practice in Swiss pathology laboratories. Recently, testing 
for BRAF mutations has been introduced as a result of 
growing evidence of predictive and prognostic value in 
mCRC patients considered for antibody treatment8, 16, 53, 54. 
Our results add to the rationale for these approaches.  
Predictive tests need to have appropriate sensitivity and 
specificity. For KRAS and BRAF, sequencing analysis is 
frequently used, as was assumed in our model55. Direct 
sequencing analysis is characterised by its potential to 
detect all mutations, leading to very high specificity23. On 
the other hand, this method may feature a lack in 
sensitivity compared to other techniques55. In 
consequence, some patients with KRAS or BRAS 
mutations may still receive anti-EGFR treatment.  
Further EGFR downstream regulators have been 
associated with lack of response to monoclonal antibodies 
in mCRC, e.g. loss in PTEN expression3 or PIK3CA 
mutation11. However, the evaluation of PTEN requires 
more standardization and is not yet ready for the clinical 
setting11, 56. Furthermore, the real predictive value of 
PIK3CA mutations is not firmly established57.  
Cost-effectiveness thresholds for clinical interventions vary 
between countries. Threshold values of $50’000-$100’000 
(€38’500-€77’000) per QALY gained (USA) or £20’000-
£30’000 (€23’000-€35’000) per QALY gained (UK) are 
regarded as realistic58. Mittmann et al. conducted an 
economic evaluation of cetuximab therapy for mCRC 
patients37. In a sub-analysis, they assessed cetuximab 
versus BSC in KRAS wild-type patients. The resulting 
ICER of €144’360 (CI: €100’737-€258’896) per QALY 
gained is unfavorable compared with our result. The 
authors found a QALY difference of 0.18, which is about 
half of our estimated QALY gain. A likely reason for this 
apparent discrepancy is that Mittmann et al. restricted the 
time horizon of their analysis to the observation period of 
the CO.17 trial (18-19 months, during which 77% and 82% 
patients in the cetuximab and BSC arms died, 
respectively)33, 37. In contrast, our model used a life-long 
time horizon, in line with good health economic practice for 
the assessment of interventions with life-long 
consequences or an impact on survival59. Taking into 
account the full survival experience of all patients inclusive 
of longer-term survivors, using appropriate modeling 
techniques, lead to a higher accumulation of QALYs 
gained and is likely to explain our more favorable ICER 
results. 
A further health economic analysis found an ICER of about 
€70'000/QALY for cetuximab in combination with 
chemotherapy41. This analysis did not differentiate 
between KRAS mutant and wild-type patients, although it 
was mentioned by the authors that factors specific to the 
patient population should be considered. 
Some limitations of our study are related to data 
availability. Starting with a clearly defined patient 
population, we tried to identify the most appropriate model 
inputs currently available from the literature. However, 
clinical evidence from biomarker-based randomized trials 
is scarce in the colorectal cancer setting. Hence, clinical 
and utility data originated from few studies conducted 
outside Switzerland8, 32, 33, 37. As one consequence, 
available quality of life and utility data allowed to 
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differentiate on the basis of cetuximab treatment versus 
BSC, but not on the basis of mutation status. Given that 
both BRAF and KRAS mutation is associated with a similar 
lack of response to cetuximab, similar quality of life was 
assumed in non-responders as in BCS-treated patients. 
Furthermore, differences in QALY results originated mainly 
from differences in survival time due to mutation status and 
treatment given. This instance has been fully incorporated 
into our analysis. Information on clinical resource use was 
primarily clinical trial-based and deviations from routine 
practice patterns may occur. However, varying the use of 
diagnostic procedures in the BSC group did not impact the 
main result.  
Of note, this economic analysis is focusing on patients with 
late stage, chemo-refractory cancer. Latest evidence 
implies that cetuximab first-line treatment of mCRC leads 
to significant response in KRAS/BRAF wild-type patients60. 
However, BRAF mutation seemed to have no impact on 
response to the antibody, suggesting that BRAF mutation 
may not have the same predictive value in first-line and 
chemo-refractory tumors.  
In conclusion, testing for KRAS and BRAF mutations prior 
to cetuximab treatment of chemorefractory mCRC patients 
is clinically appropriate and economically favorable, 
despite high costs for predictive testing. 
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Table 1.Strategies and characteristics of predictive tests  
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BSC, best supportive care; CET, cetuximab; Mt, mutant; wt, wild-type.  
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Table 2. Clinical input parameters: survival according to mutation status and treatment strategy  
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BSC, best supportive care; CET, cetuximab; Mt, mutation; wt, wild-type; PFS, progression free survival; OS, overall survival.  
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Table 3. Base-case cost-effectiveness analysis of different testing strategies  
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*Relative to the strategy with the next lower cost 
aCompared to the reference strategy (no CET), bCompared to KRAS/BRAF, cCompared to KRAS 
CET, cetuximab; ICER, incremental cost-effectiveness ratio; QALY, quality adjusted life year.  
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Figure 1. Overview of Markov Model  
 
CET, cetuximab; Ref, reference strategy 
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Figure 2. Base case cost-effectiveness analysis  
 
CET, cetuximab; Ref, reference strategy; QALY, quality adjusted life year 
79   
 
Figure 3. Probabilistic sensitivity analysis (Acceptability frontier*)  
 
*The cost-effectiveness acceptability frontier shows the PSA-based probability of strategies being cost-effective. For different 
willingness to pay thresholds, different strategies are optimal. For each threshold, only the probability for the optimal strategy is 
shown. The no-testing strategy (not displayed in the figure) becomes at no threshold value the preferred strategy. Ref, reference 
strategy; prob, probability 
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Appendix 1. Medical resource use and cost data 
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1)starting dose 
2)maintenance dose 
3)cetuximab and BSC patients were assumed to require weekly and monthly outpatient visits, respectively.  
4)average length of stay of patients admitted to a Swiss hospital with a diagnosis of ICD-10 C180-200 , during 2005.  
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Appendix 2. Results of the deterministic sensitivity analysis in regard to parameter uncertainties
BSC, best supportive care; CET, cetuximab; Mt, mutation
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Appendix 3. Deterministic sensitivity analysis of incremental costs (EUR) per QALY gained (ICER) (Scenario analysis) 
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**Assuming that patients had magnetic resonance imaging, radiologic imaging and cross-sectional imaging at the time of 
treatment decision (model entry), but no subsequent diagnostic tests. 
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Appendix 4. Incremental cost-effectiveness scatterplot of KRAS and BRAF versus no certuximab (QALY, 
quality adjusted life year) 
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Part V – General discussion  
In Switzerland, cancer is the second most common cause of death, with about 31’000 new cases and 
15’000 cancer related deaths every year. Men are mainly affected by prostate, lung and colon cancer, 
whereas in women breast, colon and lung cancer are the most common types161.  
In recent years, health-care payers have been faced with increasing cost pressure162. According to the 
Federal Office of Public Health (FOPH), the Swiss health system accounted for about CHF 55.3 billion 
(! 42.1 billion) in 2007. Correspondingly, 10.8% of the gross domestic product (GDP) was spent on 
the health care sector. This proportion has increased by about 5.4 percentage points since 1970163. 
The financial burden of cancer is considerable. Cancer drugs account for about 10% of the total costs 
of prescription only medicaments in Switzerland164. One attempt to respond to this problem in the field 
of oncology is the development of biomarker-based and pharmacogenetic approaches, including new 
diagnostic innovations. These approaches strive for selecting patient sub-groups who will most 
probably obtain a maximal clinical benefit, while reducing possible adverse events among those who 
are less prone to benefit from a given treatment. Withholding potential cancer therapies from patients 
may result in excess recurrence rates and deaths. However, overuse of the drug by administering it to 
non-responding patients yields in avoidable risk of side effects and incurs unnecessary health care 
costs165 102.  
The primary criteria for applying diagnostic assays are test performance and predictive and/or 
prognostic values. This means that the choice of the test strategy or an assay depends upon the level 
of information on the relative response rate of selected patients. Costs, availability and ease of 
utilisation are of secondary consideration79. The use of predictive tests has emerged and implicates 
the potential of improving the quality and efficiency of targeted health care166. Clinically useful 
predictive tests with reasonable sensitivity and specificity to predict drug-response are one 
cornerstone in achieving a cost–effective implementation of new treatment strategies in oncology.  
Markov models can assess clinical benefits and adverse effects of therapies measured in quality-
adjusted life-years; the observed response to the therapy with various testing methods; and the cost of 
testing, monitoring, and treatment. This is particularly important for decision making in selecting test 
strategies with different sensitivities or specificities.  
1. Cost-effectiveness of HER-2 test assays 
There is a long debate in the literature, which HER-2 test should be performed. Arguments pro and 
contra specific tests or their combinations include sensitivity of the tests, reliability in FFPE tissue 
samples, treatment response, reproducibility between laboratories, and health cost considerations79. 
Both, erroneously treating women whose breast cancers lack HER-2 or failing to treat HER-2 positive 
women, should be prevented.  
There is only little evidence about the usage of HER-2 tests and their health economic implications. 
This is not only true for Switzerland, but also for other European countries or the USA. A recent review 
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identified cost-effectiveness studies of HER-2 test strategies in the clinical practice of the USA166. By 
screening 621 studies, only four publications matched the search criteria. Studies examining the 
health economics of HER-2 tests in the adjuvant setting were not identified. Only one study assessed 
several potential testing strategies in the metastatic breast cancer setting167. In our publication168, we 
have addressed the existing cost-effectiveness studies in more detail.  
In the first part of my study programme, the costs and clinical implications of various HER-2 testing 
regimens were modelled, prior to antibody-based cancer treatment (i.e. trastuzumab) of adjuvant 
breast cancer patients. The study evaluated the costs and effects of assessing the HER-2 status by 
IHC and/or FISH to identify patients who are unlikely to respond to therapy from a Swiss healthcare 
perspective. The study clearly favours the FISH assay as the main strategy (ICER: ! 12’245/QALY 
when compared with no trastuzumab use)168. The present analysis was the first to address the health 
economic impact of HER-2 testing in Switzerland.  
1.1. Limitations of the study 
There are some limitations of the study which should be mentioned. One limiting factor is the available 
data sources. Starting with a clearly defined patient population, I tried to identify the most suitable 
model inputs available from the existing literature. Data from different sources were selected for the 
modelling. For some of the parameters existing data vary to some extent (e.g. test characteristics of 
HER-2 by FISH or IHC). The crucial key element of an economic study is the selection of a reliable 
data basis which is incorporated in the final model. Sensitivity and specificity of the HER-2 testing, but 
also the utilities of each health state were critical key elements in the outcome of the analysis. Various 
sensitivity analyses have been performed to assess the robustness of the study result. Key limitations 
were addressed in the publication168 but the level of detail was restricted due to word limitations. For 
giving the full picture of all critical points, I am going into more detail in the following section.  
I performed a thorough literature review and was in close collaboration with clinicians and experts in 
the field of oncology. HER-2 positive patients are well known to have a worse prognosis due to shorter 
disease-free and overall survival both in node-positive and node-negative breast cancer81 97 169 170 as 
well as lack of responsiveness to cytotoxic chemotherapies92 171. The data retrieved and incorporated 
into the model fit very well. The following rationale was applied in order to select and include the most 
appropriate data available in the published literature. The selection criteria for studies informing path- 
and transition probabilities were (1) randomised controlled clinical trials or published retrospective 
reviews of medical records, (2) studies with sufficient power, and (3) providing the required information 
(data points). Exclusion criteria were studies on phase II trials, conference abstracts, studies with very 
low sample size, studies of cancer therapies with monoclonal antibodies targeted against HER-2 other 
than trastuzumab and publications with insufficient information. For specific transition probabilities I 
have used the following data bases:  
• Disease free: For information on disease progression out of the disease free health state I 
chose to incorporate the HERA trial in the model (as explained below). 
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• Regional/ local recurrence: Data sources were sparse for transition probabilities of patients 
with a regional or local recurrence. The studies by Harris et al.172 and Shen et al.173 were 
used. I was not aware of any other data source that would have allowed to extract the required 
amount of information.  
• Distant recurrence: Using two studies providing progression rates according to HER-2 status 
and trastuzumab administration status, I was able to retrieve information on stable disease 
and mortality rates of metastatic breast cancer patients as required for the modelling96 174. 
There are other publications available97 175-178, but the results were consistent with these 
studies. The publications by Slamon et al.96 and Seidman et al.174 were the only reports of 
randomised phase III trials of trastuzumab plus chemotherapy versus chemotherapy alone in 
metastatic breast cancer patients which enabled me to extract the information required for the 
modelling.  
Modelling the disease free survival was based on the HERA trial, which assumed that HER-2 positive 
patients receiving trastuzumab treatment would have the same transition probabilities as patients 
receiving adjuvant trastuzumab in HERA99. In HERA, HER-2 positive patients were verified by IHC 3+ 
or FISH confirmation of IHC 2+ results. Accordingly, our analysis assumed that the same event risks 
were obtained with trastuzumab (i.e. the same transition probabilities have been applied to in the 
Markov model) in each of the combinations of FISH and IHC being tested. This implies that the HERA 
trial implicitly sets up a gold standard whereby the assumption of HER-2 positivity or negativity is 
made according to the results of the testing done in that trial, and the trial data applies to the patients 
identified. Hence, I did not take account the possibility that the event risk in HERA would have been 
different had a different system of HER-2 testing been used in that or other trials. When patients were 
identified by different test regimens and HER-2 positivity and negativity is not accurately predicted by 
this standard there could be a possibility that the measured benefits of trastuzumab would be different, 
namely less, than in the HERA study because of the different pattern of false positives and false 
negatives. Correction of these factors in each case would have required the determination of the “real” 
HER-2 status and the assumption of the benefit only in the true positive samples. The breast cancer 
model assumed that the same transition probabilities have been applied to each of the combination of 
IHC and FISH tests. It could be argued that the measured benefits of trastuzumab would be altered in 
the different test strategies, due to the fact of the variable pattern of false positive and false negative 
cases, as described above. This process would have needed complex modifications of the Markov 
model. By using hypothetical estimations, the effect on the base case result was only minor. 
It should be noted, that the Breast Cancer International Research Group (BCIRG) clinical trial-data110 
was used as reference for FISH and IHC, but follow-up-data (i.e. survival times, risk of recurrence) 
after trastuzumab treatment was derived from the HERA trial99. Nevertheless, the assessment of 
sensitivity and specificity of test strategies does not depend on the effectiveness of trastuzumab 
treatment. Hence, no bias was introduced into the model by using the publication of Press et al110 to 
extract data on sensitivity and specificity of IHC and FISH testing for HER-2 expression. I have chosen 
this basis for the following reasons: (1) there are only very few papers which discuss the sensitivity 
and specificity of these testing strategies; (2) the work by Press et al110 is well accepted among 
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pathologists; (3) Press et al110 provided the important information on false positive and false negative 
HER-2 testing results, which ultimately allowed me to model differences in clinical effectiveness 
(expressed in QALYs); and (4) the study was conducted with a considerable sample size (n=2600). 
Data on progression rates of HER-2 positive disease free patients treated with or without trastuzumab 
were derived from the HERA trial99, due to the fact that the efficacy of trastuzumab in early breast 
cancer patients was presented in sufficient detail and allowed to inform the modelling of different 
health states in the health economic model (death, regional, local and distant recurrence). The 
BCIRG- studies179 were not used as follow-up data as the published trial results did not provide me 
with the data requested for the model. Furthermore, some trials were not in accordance with the 
inclusion criteria mentioned above.  
HER-2 positivity rate was assumed to range between 15% and 25%81 88 90 180. In the base-case, I 
assumed a HER-2 positive cohort of 20%. This rate has been varied within a range of 5% in diverse 
sensitivity analyses. However, there is recent evidence to suggest that the HER-2 expression level in 
the primary tumour differs from the invasive tumour tissue181-185. A discordant rate of about 5% to 10% 
is discussed. Accordingly, the data propose that the rate in early breast cancer is around 15% up to 
20% while the rate in metastatic breast cancer is around 20% to 30%. This would imply a 
reassessment of the HER-2 status before treating advanced breast cancer patients. In addition, the 
sensitivity and specificity of the HER-2 testing regimens would probably need to be adapted according 
to the metastatic setting. Given the scarce data availability, I did not assess a HER-2 re-testing of 
patients in the metastatic cancer state.  
Trastuzumab treatment duration of one year was assumed, which is the planned treatment schedule 
and also stated in the label186. Still, in the HERA trial 8.5% stopped treatment with trastuzumab before 
the completion of the one-year treatment period. Reasons were side effects, rejection or others99. 
Given that no information on mean or median treatment duration was available, I was not able to 
adapt the actual treatment time to the model. Moreover, there is evidence of anthracycline-based 
cardiac toxicity due to trastuzumab in combination with anthracycline chemotherapy96 99 100. 
Nevertheless, I did not take account possible side effects of trastuzumab or the standard 
chemotherapy, respectively. The main reason was the uncertain and inadequate data available for an 
accurate assessment in the Markov model.  
The model evaded to assume any efficacy of trastuzumab administration to HER-2 negative patients. I 
have recognised that several open questions remain about the role of trastuzumab in treating breast 
cancer patients187 188. In the published literature, there are only a few studies addressing this topic. 
Seidman et al reported a randomised controlled trial showing no effect of trastuzumab in tumours 
lacking HER-2 overexpression or gene amplification174. However, study results from the National 
Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-31189 provided a counterbalance to 
the above mentioned study. Paik et al suggested that benefit from trastuzumab may not be limited to 
HER-2 positive patients, but their results were based on exploratory analyses and need to be verified 
in a phase III study189. Nevertheless, the concern of wrongly mislabelling patients as HER-2 negatives 
remains.  
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The present analysis adopted a Swiss health system perspective. This is an approach which is widely 
used in pharmacoeconomic evaluations. Hence, no indirect costs (e.g. loss of productivity) have been 
included. The loss of salary due to treatment-related absences from work is one of the greatest costs 
induced by the disease especially for cancer patients190. Most available data sources on indirect costs 
are based on conventional chemotherapeutic interventions. One was not able to estimate the extent of 
indirect costs for patients treated with trastuzumab. Therefore, the estimation of the indirect costs 
would be subject to great uncertainty. Furthermore, costs of the adjuvant chemotherapy were not 
incorporated. I expected that patients, regardless of trastuzumab administration, would have the same 
chemo-regimen resulting in any chemotherapeutic cost-difference in the treatment groups. The costs 
of aromatase inhibitors were included in the analysis as its administration varies according to the HER-
2 status.  
1.2. Test algorithm: points to consider 
Recently, the American Society of Clinical Oncology and the College of American Pathologists 
(ASCO-CAP) recommend that HER-2 status ought to be determined for all invasive breast cancer, 
without giving priority to one test method102. They recommended either to use IHC assays for initial 
evaluation of HER-2 status followed by reflex FISH testing of some IHC categories or primary use of 
FISH in initial testing. Both assay methods have technical shortcomings resulting in different 
sensitivities and specificities of HER-2 testing. Our results support a previously published review 
favouring FISH over IHC testing for accuracy, reproducibility and precision reasons79. HER-2 gene 
amplification can be directly connected to the expression level of HER-2 protein79. Additionally, a 
positive FISH status points towards a much stronger responsiveness to trastuzumab. The use of FISH 
testing diminishes the number of patients eligible for trastuzumab therapy due to both superior 
sensitivity and specificity compared to IHC79.  
Evaluation of testing for HER-2 status should consider costs of treatment and testing as well as 
potential benefits of targeted therapy. FISH assays are significantly more expensive than the IHC 
assessment of HER-2. This is frequently used as an argument against primary FISH testing. 
Nonetheless, costs of diagnostic tests are minimal compared to the substantial costs of the therapy. 
This is especially important when considering that the cost of trastuzumab is approximately US$ 1’000 
(equalling ! 830) per treatment once a week for 52 weeks191. The present Markov model with an 
analysis of total costs and benefits clearly supports primary FISH testing as the most cost effective 
approach for patient management. However, the debate of whether IHC or FISH testing is more 
appropriate for the identification of HER-2 status cannot be solved by cost arguments only.  
1.2.1. HER-2 testing in routine practice 
In routine practice, many local laboratories only use IHC. Those patients with a positive IHC receive 
trastuzumab treatment. Numerous central laboratories use FISH for reflex testing of problematic IHC 
2+ samples for quality assessment, as was the case in the HERA study99. In the USA, it is currently 
estimated that 80% of the HER-2 tests start initially with IHC and the rest is using FISH in the first 
instance192. However, both of these strategies were clearly dominated by the FISH testing regimen, as 
shown by our modelling results.  
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In Switzerland, many central laboratories have started to use FISH as the primary test. IHC is only 
added for equivocal cases. The strategy of verification FISH equivocal cases by IHC is difficult to 
assess, as no test sensitivity or specificity data for FISH equivocal samples (HER-2/CEP17 ratio signal 
between 1.8 and 2.2) were available from the literature. By using a tentative assumption of a 
theoretical sensitivity of 0.892110 193, the clinical effectiveness yielded in 12.470 QALYs. Consequently, 
it can be assumed, that such a strategy would not achieve a further clinical benefit when compared to 
FISH alone. This aspect was comprehensively discussed in our publication168.  
1.2.2. False positive and false negative test results  
Patients with false positive test results will be treated with the monoclonal antibody-based therapy 
although their benefit will be marginal. This may result in additional costs as well as risk of adverse 
events such as cardiac toxicity96. On the other hand, false negative results may have serious 
consequences for the cancer patient’s prognosis. Approximately 3% to 4% of all early breast cancer 
patients are falsely negative192. Given that those patients do not receive anti-HER-2 targeted therapy, 
this implies an increased relapse rate or even death from failed adjuvant treatment. By sustaining high 
assay sensitivity, the incidence of false negative results may be kept small. In our cancer model, test 
sensitivity and specificity had a major impact on the base case result. It is not surprising, that 
treatment strategies with the highest rates of true positive results have ultimately yielded a favourable 
cost-effectiveness ratio (i.e. FISH testing).  
It is assumed that 15% to 48% of equivocal IHC (2+) breast cancers indicate amplification of the HER-
2 gene. Besides, IHC negative cases (0/1+) are FISH amplified in 2% to 8%. False positive IHC breast 
cancer samples which are lacking HER-2 amplification were found in about 5-22% cases79 194. This 
divergence may be mainly attributed to a loss in IHC sensitivity which is linked to tissue fixation195. 
HER-2 gene amplification identified by FISH is highly associated with patient survival, whereas such a 
relationship could only be found in strong immuno-stained samples (IHC 3+)81 196. In conclusion, FISH 
negative/ IHC positive patients have a similar prognosis as FISH negative/ IHC negative cases. 
Furthermore, FISH-positive/ IHC-negative breast cancer patients have a survival probability which is 
comparable to that of FISH-positive/ IHC-positive cases195, as was assumed in our modelling analysis.  
1.2.3. Novel test assays for HER-2 determination 
There is a demand for 
new approaches for 
HER-2 status evaluation 
to amend the selection of 
patients treated with 
monoclonal antibodies. 
As a consequence, 
emerging new bright-field 
in situ hybridisation techniques for HER-2 assessment are currently being introduced102. Silver 
enhanced in situ hybridisation (SISH) compensates some shortcomings of FISH. This technique is 
characterised by a combined assessment of HER-2 and a chromomeric detection of chromosome 17, 
Figure 10. Chromogenic in situ hybridisation (CISH) on a breast carcinoma. a) normal 
HER-2 copy number; b) low level of HER-2 gene amplification (6 copies of HER-2 
gene/cell); c) high level of HER-2 gene amplification. Resolution: 1000x. Adapted from van 
de Vijver et al, Breast Cancer Res. 2007.  
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its signal permanency and the usage of a bright-field microscopy to analyse the result197 198. The costs 
of SISH are, however, comparable with FISH. Similarly, chromogenic in situ hybridisation (CISH; 
SPOT-Light®, Invitrogen Corporation, Carlsbad, CA) identifies the level of HER-2 gene amplification 
by using a peroxidase-based chromogenic reaction, comparable with IHC (Figure 10)199. Accordingly, 
CISH results are determined by using a light microscope. Inter- and intra-laboratory concordance rates 
to establish testing techniques (IHC, FISH) are considered high, even in IHC equivocal cases199 200. 
Considering FISH as “gold standard”, CISH proves sensitivity and specific rates of 85% (95% CI, 
73%–95%) and 100% (95% CI, 100%–100%), respectively201. The HER-2 CISH kit was approved by 
the FDA in 2008103. Due to the fact that all clinical trials included in our model have not used CISH in 
assessing the HER-2 status of their patients, a CISH strategy was not included in the model. 
Furthermore, the CISH kit had some shortcomings and is not routinely used in all laboratories in 
Switzerland.  
A recent technique which quantifies HER-2 expression and HER-2 homodimerisation in FFPE tissues 
is the HERmark Breast Cancer Assay (Monogram Biosciences, South San Francisco, CA)202. 
HERmark showed in a recent study high concordance (98%) with IHC positive and negative test 
results. Future studies are needed to assess the comparison of HERmark and FISH test assays from 
IHC negative, equivocal or positive cases203.  
2. Cost-effectiveness of metastatic breast cancer therapies 
Herewith, the second publication (review article)204 will be discussed.  
While early breast cancer is fairly treatable, advanced cancer stages have a worse prognosis. If 
cancer cells metastasise to distant areas of the body, the patient may be treated, but not cured205. 
Currently, many ongoing studies measure the clinical effect of new therapeutic interventions in the late 
state disease of breast cancer patients. It is crucial to understand not only the clinical value but also 
the economic impact of new and existing treatments. In the UK, the annual costs of new metastatic 
breast cancer cases are estimated at £ 22 million (! 23 million) for 2002. For the prevalent population, 
treatment costs of about £ 245 million (! 308 million) are proposed206.!!
Currently, many studies are dealing with cost and effectiveness of diverse novel treatment regimens 
for advanced breast cancer treatments. In the review article204, I have reviewed pharmacoeconomic 
studies with regard to chemotherapy and targeted therapies for metastatic breast cancer patients. 
Endocrine therapy is generally given as first choice in the treatment of hormone receptor-positive 
patients207. Of note, in the review, I did not focus on endocrine treatment regimens. The review did not 
only focus on the incremental cost-effectiveness ratio achieved but moreover on the quality of the 
health economic evaluations. The key modelling parameters were also critically assessed. The 
guidelines described in section 1.7. (Assessing quality aspects of health economic studies) built the 
basis of the critical appraisal.  
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2.1. Treatment of metastatic breast cancer  
The primary aim of treating metastatic breast cancer patients is mainly prolong survival, mitigate 
symptoms, and maintain quality of life208. The treatment of advanced breast cancer is not 
standardised. Patients can be treated with a single agent (monotherapy) or with a combination of 
agents, or single agents in sequence in order to diminish toxicity209. For the treatment of HER-2 
positive cancer patients, trastuzumab is mainly used as first-line therapy in combination with or without 
chemotherapy210.  
2.2. Limitations of the review 
There are some limitations associated with the present review. I included pharmacoeconomic studies 
from peer-review literature. The search of the studies was limited in terms of the database (MEDLINE). 
It can be assumed, that the database accessed maintains the majority of scientific full text articles. 
MEDLINE is considered the key source for reviews in terms of economic evaluations211. Hence, other 
databases such as CRED Evaluation Database and Embase were not searched. For the sake of not 
omitting important studies in this field, I consulted the reference list of the selected or related 
publications. This gave the review a broader basis. By manual searches and searches in databases 
other than MEDLINE some further studies might have been found, but the amount of additional 
information missed was assumed to be marginal211.  
The search criteria did exclude studies not written in English, as it is the general use in scientific 
review articles. Furthermore, I did not carry out a “gray literature search”, i.e. searching for studies 
which were not available in peer-reviewed journals. Consequently, information published by 
organisations or presented as abstracts at scientific meetings were omitted. This kind of information 
was not regarded as academically rigorous as the information which is available in peer-reviewed 
journals. I am aware that this may have lost some emerging new evidence of research. Nevertheless, 
with the information provided in an abstract, I would not have been able to extract information required 
for the sake of the quality assessments of the study. In the majority of meeting-abstracts, only scarce 
information on methodological issues is provided. This made it impossible to critically appraise the 
modelling process and the parameter values included in the analysis.  
The studies included were of diverse methodological rigor. The results of the cost-effectiveness 
studies could hardly be compared with each other, as they all originated from different countries, using 
different modelling methodologies as well as input parameters. The ICER reported for the different 
agents showed a broad spectrum. For the sake of reimbursement decisions, pharmacoeconomic 
results are usually compared to reference thresholds or other cost-effectiveness analyses. The 
reference value may be based e.g. on societal willingness-to-pay levels (see also Introduction, 
1.8.1.)46.  
The health economic studies of cytotoxic therapies generally showed favourable cost-effectiveness 
ratios (i.e. rates below the threshold values). Considering the review results, no preference for the one 
or the other agent could be determined. Targeted therapies, in particular trastuzumab, showed 
favourable and non-favourable results. Given that most information on the health economic impact of 
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targeted non-chemotherapeutics for metastatic breast cancer treatment was focused on trastuzumab, 
it was inevitable to pay special attention to this agent. From a European third-party perspective, Norum 
et al212 appraised the first-line therapy of trastuzumab combined with chemotherapy as not cost-
effective (compared to chemotherapy alone in HER-2 positive patients). In contrast, NICE evaluated 
trastuzumab treatment both as mono-therapy and in combination with paclitaxel as cost-effective for 
HER-2 positive metastatic breast cancer patients213 214. This implies that different parameters (costs 
and effects), different modelling approaches and different perspectives considerably influence health 
economic data.  
The majority of pharmacoeconomic evaluations used models based on indirect data inputs from the 
published literature. The associated limitations with modelling have been discussed extensively (see 
Introduction, 1.6.). Nevertheless, the realisation of pharmacoeconomic studies requires the 
assessment of best practices for the sake of quality of evidence215. In the review article, we discussed 
the underlying data that were used in the models to assess whether the assumptions are credible, 
relevant (incremental) costs and effects were included, and how studies extrapolated e.g. progression 
free survival to life-years gained.  
Most studies have not included indirect costs because of their chosen perspective (e.g. third party 
perspective). Notably, for metastatic breast cancer patients the work capacity is limited. Often, they 
are forced to go into early retirement216. Moreover, the economic and occupational burden of care 
givers is substantial217. The perceived burden has been shown to be negatively associated with the 
functional status of the breast cancer patients.  
I only included studies published since the year 2000 in order to have a comparable study population 
in both the conventional and targeted treatment setting. Nevertheless, some of the studies were 
conducted before generic tamoxifen or paclitaxel were available. This implies that current drug costs 
may be lower than reported in these studies. The conclusion on whether an agent is cost-effective 
may vary according to price-cuts in some countries or new dosing schemes.  
2.3. Concluding remarks 
The actual cancer treatment patterns have an enormous influence on the costs and effects of cancer 
therapies in the metastatic setting. In order to efficiently utilise resources in the management of 
advanced breast cancer, it is crucial to better understand the health economic implication of those 
interventions. Pharmacoeconomic evaluations are one key element in providing important information 
to physicians, patients, insurers, pharmaceutical and other industries, healthcare policy planners, and 
others218. The present review suggests that gaps in the literature especially with regard to high quality 
economic models are considerable. There is an implicit need of studies, evaluating the 
pharmacoeconomics of current cancer drugs and how they might change the current clinical practice.  
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3. Health economic implication of testing for KRAS and BRAF 
mutation 
The introduction of molecular tests into the clinical management of metastatic colorectal cancer 
patients which are treated with EGFR-targeted drugs, is a great goal achieved by researchers. These 
predictive tests are very important for the identification of patients who might benefit from these 
agents, but they are also rather expensive. In order to validate whether molecular tests on the 
management of metastatic colorectal cancer are economically favourable, I assessed in my second 
PhD study programme the costs and effects of different testing strategies for KRAS and/or BRAF prior 
to cetuximab treatment of metastatic colorectal cancer patients (third paper, submitted manuscript). 
Costs were considered from the perspective of the Swiss health system. By using a life-long Markov 
simulation model, the sequential approach with BRAF testing of all KRAS wild-type patients was 
identified as the test strategy with the most favourable incremental cost-effectiveness ratio of the 
approaches investigated (ICER: ! 67’779/QALY compared to no cetuximab). The present work is the 
first study assessing the health economic implications of testing for KRAS and/or BRAF gene 
mutations in metastatic colorectal cancer. The strengths of the study include the evaluation of a 
clinically relevant policy topic and high quality data sources.  
3.1. Limitations of the analysis  
In the manuscript of the second part of my PhD programme the main limitations have been discussed. 
Some of these and some further points are elucidated here. 
First of all, cetuximab is not the only EGFR-targeted therapy approved for the treatment of advanced 
colorectal cancer patients, although it represents the most common choice. Hence, I could have run 
the entire model with other monoclonal antibodies targeted against EGFR, as e.g. panitumumab 
(Vectibix®, Amgen, Inc). Randomised controlled phase III studies indicated similar effects with this 
drug, which allowed to assume that using another targeted therapy would achieve comparable 
outcomes. My first interest was to provide information on the impact of predictive test strategies before 
using antibody therapy. I was not focusing on whether one drug was superior to an alternative 
treatment. 
Some further limitations are related to the availability of the included data. I started by clearly defining 
the patient population of interest and tried to determine the most suitable model inputs available from 
the published literature. Due to the fact that clinical evidence from pivotal studies is limited, I mainly 
used clinical efficacy from trials conducted outside of Switzerland121 129 219 220. The model assumed that 
patients with BRAF mutation receiving best supportive care would have the same transition 
probabilities as patients receiving best supportive care with a KRAS mutation129. This postulation is 
based on similar non-response of KRAS and/or BRAF mutated tumours to EGFR-based agents141. To 
the best of my knowledge, there is no real world data available on the response rates of untreated 
patients harbouring BRAF mutation, backing this assumption.  
94 Part V – General discussion 
 
Data on utility as well as quality of life were restricted. Information on utility came from the CO.17 trial 
conducted by the National Cancer Institute of Canada Clinical Trials Group219. Compared to 
Switzerland, there might be some differences in the clinical treatment schedule or perception of quality 
of life. However, while being aware of this limitation, I have included the foreign data as the best 
available source of clinical evidence. One was able to distinguish utilities according to the treatment 
received but not on the basis of mutation status. Given the fact that both BRAF and KRAS mutation is 
linked with a comparable lack of response to anti-EGFR therapies141, the quality of life in non-
responders was assumed to be similar to patients treated with best supportive care. In the base case 
analysis the differences in the QALY results were primarily driven by the variation in survival times 
determined by the mutation status and anti-cancer therapy. This instance has been fully integrated 
into the analysis.  
Information on the prognostic compared to predictive value of BRAF was derived from various studies. 
Until now, there is broad discussion on whether BRAF is a firm molecular marker. It is not entirely 
clear to what degree BRAF is prognostic for outcome with no treatment or predictive for the result of 
cetuximab treatment. Clinical research showed strong evidence favouring BRAF testing141 220. 
Furthermore, in Switzerland, BRAF testing has only entered the laboratories of pathologies recently. 
To bear with the uncertainties regarding the genomic association data for BRAF, numerous sensitivity 
analyses have been carried out to assess the robustness of the study results.  
The Markov model used a time frame, which was life-long for the base case analysis. Yet, I based the 
assumptions of the overall survival rate and risks for progression on clinical trials which had a shorter 
time frame129 219 220. It is argued that the life-long scenario is associated with more uncertainty and in 
general a better cost-effectiveness ratio221. Nevertheless, the life-long approach is in line with good 
health economic practice for the evaluation of interventions with life-long consequences or a survival 
influence222. In a sub-analysis I determined the cost and effects of using a time frame of 18 months, 
which is also in agreement with the trial duration of CO.17219. Testing for KRAS and BRAF remained 
the preferred strategy with an ICER of ! 108’425/QALY compared to the reference of no cetuximab. 
The next best strategy was KRAS testing yielding a much higher cost-effectiveness ratio (! 
580‘263/QALY compared to KRAS/BRAF testing). These results agree in principle with the results 
found by Mittmann and colleagues who conducted an economic within-trial analysis of cetuximab 
therapy compared to best supportive care in KRAS wild-type patients (! 144’360 per QALY gained)219. 
Their analysis was restricted to the observation period of the CO.17 trial (18-19 months)121 219. They 
calculated an ICER which is much higher than my life-long base-case results, but similar to my short-
term analysis. The favourable ICER in my base-case analysis can be attributed to the fact of a higher 
accumulation of QALYs gained due to the incorporation of the full survival experience of all patients 
inclusive of longer-term survivors. In addition to this, the Canadian study did not include the costs of 
the mutation testing, as all patients in their cohort were tested. However, extrapolating their estimates 
to the general population would require the inclusion of the test costs223. This approach is of particular 
importance when different test assays, different biomarkers and different test strategies are taken into 
account, which was the case in my analysis.  
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Data on clinical resource use was mainly based on the information derived from clinical trials, but 
divergence from routine practice patterns may occur. In a sub-analysis, I varied the usage of 
diagnostic procedures in the best supportive care group but could not find an influence on the base 
case results. Moreover, resource usage was discussed extensively with clinical practitioners for its 
appropriateness. For an accurate assessment of the costs to the Swiss Health Care System, costing 
data (including hospitalisation) derived from the official Swiss tariff book (Tarmed), official Swiss 
pharmacy prices and Swiss hospital statistics were used224 225 226 227.  
There are studies which have provided information on adverse events of cetuximab treatment138 219. It 
can be assumed, that avoiding such effects in non-responders is another important benefit of 
predictive testing. As in the breast cancer model168, I realised that I could not fully include this aspect. I 
have, however, indirectly taken into account some costs of adverse effects by including times of 
hospitalisation which may have been, at least in part, related to treatment toxicity. 
Given the third-party perspective of the analysis, indirect costs were not included. Nevertheless, it 
should be noted that indirect costs as e.g. productivity loss may have considerable influence on the 
economic burden of the disease, but they are hard to measure. Recent research identified that most of 
the working non-metastatic colorectal cancer patients return to work. About 17% quit workforce which 
can be mainly attributed to worse prognosis or low socioeconomic status228. Hence, it is unsure, to 
what extent, patients on cetuximab last-line therapy are capable to hold an occupation or are able to 
continue to work. Moreover, patients receiving cetuximab have to visit the hospital on a weekly basis 
which implies increased productivity costs. Noteworthy, the economic burden of informal care givers of 
colorectal cancer patients can be assumed as considerable229. In a cross-sectional survey, Van 
Houtven and colleagues measured the economic implications in terms of opportunity costs of 
caregiver time, the value of lost work hours and out-of-pocket expenditures. Depending on the 
patient’s disease phase, the economic burden for caregiver ranged between US$ 7’028 (! 5’493) and 
US$ 14’234 (! 11’125).  
The strength of the present analysis is the distinction of different testing strategies and their impact on 
the cost and effects in the EGFR-targeted colorectal cancer treatment. There are no studies available 
which examined different testing strategies including BRAF mutation analysis.  
3.2. Emerging clinical evidence  
3.2.1. Novel potential molecular markers  
On one hand the activation of downstream EGFR pathways is mediated by KRAS and BRAF and by 
PIK3 on the other hand. However, absent KRAS and/or BRAF mutations do not warrant response to 
monoclonal antibody treatments. The sensitivity to these drugs demands for wild-type KRAS/BRAF 
phenotype, but there are still patients, who do not respond to cancer therapy with cetuximab or 
panitumumab127. This indicates that other molecular targets might be involved in the downstream 
pathway of EGFR. Due to the complexity of the signalling pattern, it is likely that future predictive test 
assays will include several molecular biomarkers before antibody treatment. There are further 
candidates discussed by the scientific community for refining the responding patient population 
96 Part V – General discussion 
 
including the expression level of EGFR copy number and expression levels of EGFR ligands, loss of 
phosphatase and tensin homolog (PTEN) or markers of the angiogenesis and cell cycle regulation as 
the vascular endothelial growth factor (VEGF), Interleukin-8 (IL-8), cyclooxygenase-2 (COX-2), cyclin 
D or nuclear factor kappa B (NF"B)230. However, the validity of those makers has not yet been 
established and further research is needed. Some of these candidates will be discussed hereafter.  
Predictive testing algorithm revised 
Clearly, mutated KRAS or BRAF are not the only factors that determine response to anti-EGFR cancer 
therapy. A considerable proportion of patients can be found which neither have a mutation on KRAS 
nor in BRAF, but still do not respond to EFGR monoclonal antibodies231. This implies that new 
predictive makers in the colorectal cancer setting are of great need. The determination of BRAF, PIK3, 
PTEN or EGFR gene copy status may offer detailed information whether patients may respond to 
EFGR-targeted therapies (Figure 11) 231-233. The appraisal of costs and effectiveness of new test 
assays is pending.  
 
Figure 11. Prospective algorithm of colorectal cancer patients. GCN: gene copy number. Adapted from Sartore-Bianchi et al, 
Cancer Res, 2009.  
EGFR  
The relationship between EGFR expression level and response to anti-EGFR monoclonal antibody 
therapy has been shown to be minor122. Colorectal cancer patients not expressing EGFR, as detected 
by IHC, have a potential to benefit from cetuximab-based therapy234. The detection of protein 
expression by IHC has comparable shortcomings as already discussed in the sections above (e.g. 
fixation, storage of unstained tissue sections or methodology of IHC evaluation). Moreover, the 
expression level of EGFR is assumed to differ between the primary and the advanced tumour235. 
Given this, the predictive value of EGFR determination by IHC techniques seems to be uncertain233.  
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There is evidence, that patients with an increase in EGFR gene copy number, as determined by FISH 
or CISH, reveal a higher response to EGFR targeted therapies. Compared to patients with normal 
gene amplification, progression free survival was enhanced in those patients exhibiting a higher 
number of EGFR gene copies236 237. Hence, the detection of EGFR gene status may represent a 
predictive factor for the response of monoclonal antibody therapies targeted against EGFR (Figure 
11)233. Nevertheless, the methodological techniques have to be further standardised for achieving 
elevated reproducibility and sensitivity238.  
PTEN and PI3K 
The phosphatase PTEN de-phosphorylates phosphoinositide (PI3) and thereby controls the activity of 
its kinase (PI3K) (Figure 7). The loss of PTEN results in constitutive signalling of PI3K and apoptotic 
resistance. It has been shown that deregulated PI3K or PTEN gene as well as loss of PTEN protein 
expression conferred diminished response to cetuximab therapy in colorectal cancer patients232 236 239. 
By assessing the PTEN expression status by IHC in primary colorectal cancer patients and their 
metastatic tumours, Loupakis demonstrated considerable differences in the number and staining 
intensity of PTEN-positive cells240. In metastatic tumours, PTEN expression status was found to be 
highly correlated with tumour response and progression free survival in irinotecan and cetuximab 
treated patients. The predictive role of PTEN in KRAS mutated patients is, however, not yet validated 
and additional results from larger trials are needed24 241. Moreover, the evaluation of PTEN requires 
standardisation and its introduction in the clinical setting is not yet established (Figure 11)233.  
3.2.2. Randomised studies for first-line treatment 
Several randomised studies assessed the effect of cetuximab as first-line treatment when 
administered in combination with standard chemotherapy159 242 243. The CRYSTAL (cetuximab 
combined with irinotecan in first-line therapy for metastatic colorectal cancer) study determined 
superiority of the cetuximab-combination treatment in terms of risk of progression of metastatic 
colorectal cancer159. The benefit of cetuximab was restricted to KRAS wild-type patients. BRAF 
mutation was not identified as predictive marker for cetuximab response in first-line treatment of 
advanced colorectal cancer. The OPUS trial involved chemonaive metastatic colorectal cancer 
patients treated with cetuximab and chemotherapy (oxaliplatin) or chemotherapy alone242. The 
subgroup of KRAS wild-type patients revealed a significant survival benefit when the combination 
therapy was administered.  
3.2.3. Health economic impact of colorectal cancer management 
Drug costs for e.g. colorectal cancer may range from less than US$ 100 (! 79) to over US$ 50’000 (! 
39’081) for a six-month systemic therapy with fluorouracil/ leucovorin administered daily for 5 days 
each month and weekly cetuximab monotherapy, respectively64. Recently, Wong and colleagues 
assessed the cost implications of treating advanced colorectal cancer patients with sequential 
regimens of cytotoxic and targeted therapies67. By using a Markov model incorporating only drug 
costs, new chemotherapeutic agents resulted in an ICER of US$ 100’000 (! 79’000) per discounted 
life year (DLY). By adding antibody-based treatment regimens, the ICER increased to more than US$ 
170’000/DLY. Hence, the authors concluded that even the most effective treatment regimens lead to a 
98 Part V – General discussion 
 
high cost-effectiveness ratio. These results underline the importance of health economic evaluation in 
the field of cancer patient management. Clinically valuable predictive tests for the prediction of drug 
response are one keystone in the realisation a cost-effective implementation of new and effective 
cancer therapies. Results of pharmacoeconomic evaluations should help to inform future guidelines of 
using such tests.  
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Part VI – Conclusion 
Limited data is available on the variations in predictive testing practices in cancer care. Understanding 
the application of predictive assays is crucial in targeted cancer therapies. The present study results 
may help to inform the recent debate on advantages and disadvantages of alternative testing 
strategies for selecting patients for breast and colorectal cancer treatment schedules.  
For the Swiss setting, primary FISH testing with subsequent adjuvant trastuzumab treatment of HER-2 
positive breast cancer patients was determined as the most cost-effective and hence preferable 
approach. For the metastatic colorectal cancer patients, it is economically favourable to test both for 
KRAS and BRAF mutations before treating patients with cetuximab. The analytic framework regarding 
HER-2, KRAS and BRAF testing illustrates the challenges and opportunities in building a basis of 
evidence to sustain successful decision making about novel and emerging test assays in cancer 
management.  
We have only begun to investigate the health economic role of predictive testing. It would be of 
interest to elucidate the impact of testing in many other settings. Currently there are numerous novel 
predictive assays which are introduced into clinical pathology. Future steps may include the evaluation 
of costs and effects of testing for EGFR mutations in non-small-cell lung cancer, or for a 21-gene 
signature to predict the likelihood of chemotherapy benefit as well as recurrence in early stage, node-
negative, oestrogen receptor-positive breast cancer patients.  
The strength of these projects is that the analytic framework showed the importance of testing for the 
targets of new molecular targeted agents. By selecting patients who are more likely to respond based 
on such a predictive test result, the most efficient approach to using an expensive therapy in a 
population can be realised. 
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